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Abstract 
 
Nanomaterials used in therapy and in vivo imaging diagnostics have the potential to be highly 
specific through the use of monoclonal antibody targeting, and there are several promising antibody-
targeted nanomaterial candidates being tested in clinical trials. Numerous bioconjugation approaches 
for the attachment of antibody and antibody fragments to the surface of nanoparticles have been 
investigated.  The challenge is to create stable and reliable bio-nanomaterials, as the conjugation 
approaches are complex, require optimization, and have low conjugation efficiency.   Indeed, the 
development of an optimal and efficient method of bioconjugation is crucial for routinely producing 
hybrid bio-nanomaterials suitable for therapeutic and in vivo diagnostic applications.  
In this study, we focused on the development of bio-nanomaterial conjugates targeting 
prostate cancer as a model disease. For receptor targeting, we focused on prostate specific membrane 
antigen (PSMA), since this transmembrane protein is over-expressed in all prostate cancer stages. As 
such, PSMA is an ideal target in prostate cancer diagnosis and therapy. Therefore, in this 
investigation, we describe an active-targeting ligand for prostate cancer diagnosis and therapy, based 
on the anti-PSMA J591 antibody.   
We have developed two novel methodologies for bioconjugation of the anti-PSMA antibody 
fragment to nanomaterials to create novel targeting bio-nanomaterials. Both methods were applied in 
novel applications and provide a simplistic and efficient way to create targeted nanomaterials for in 
vivo imaging and therapy.  
In the first method, we developed a bispecific antibody (BsAb) consisting of two antibody 
single-chain variable fragments (scFvs) linked together in a tandem scFv format by a simple glycine-
serine peptide linker.  One scFv is specific for PSMA (J591 anti-PSMA antibody) and the other scFv 
is specific for methoxy polyethylene glycol (mPEG) epitopes, which are present on the surface of 
many PEG based nanomaterials, including the hyperbranched PEG polymer (HBP) used in this study. 
The BsAb was expressed in CHO cells, purified and characterized as a stable monomeric species 
based on chromatography and dynamic light scattering size analysis methods.  The BsAb could 
specifically bind to recombinant PSMA and mPEG HBP targets as determined by ELISA, as well as 
to native PSMA expressed in cancer cell lines as determined by immunoblot assays. The simple, one-
step mixing of BsAb with HBP resulted in the non-covalent formation of bio-nano conjugates through 
BsAb-mPEG binding, evidenced by a size shift of the mPEG complex as determined by dynamic 
light scattering. This study highlighted the simple and rapid BsAb conjugation strategy, 
demonstrating formation of BsAb-HBP conjugates which could target cancer cells effectively in in 
vitro assays. Furthermore, the BsAb-HBP complex, loaded with cytotoxic drugs showed an enhanced 
in vitro accumulation and cytotoxic effect compared to non-targeted HBP with drug attached. 
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However, development of this hybrid bionanomaterial proved to be complicated, as it exhibited 
different biological behaviors between in vitro and in vivo assays. The enhanced active-targeting of 
BsAb-HBP complexes vs untargeted HBP to tumors in xenograft cancer models was not as 
pronounced as in vitro assays. The BsAb-HBP also demonstrated increased localization within 
reticuloendothelial system (RES) organs, such as spleen, lungs and liver, compared to the 
unconjugated HBP. Therefore, it would suggest the need for further optimizations of ligand density 
in this antibody nanomaterial hybrid.   
The second method utilized chemoselective conjugation via the introduction of an azide-
bearing unnatural amino acid (UAA) into an anti-PSMA J591 scFv, expressed in a periplasmic E. 
coli production system. We have evaluated the incorporation of azide-bearing UAA into J591 scFv 
and investigated the ability to bind to dibenzocyclo-octyne (DBCO) containing fluorescent dye or 
polymer through copper-free click chemistry reactions. In vitro analyses showed that this azide-
modified scFv can specifically bind and internalize into PSMA-overexpressing PC3-PIP prostate 
cancer cells both independently and while bound to DBCO containing fluorescent dye or polymer. In 
vivo studies demonstrated specific binding of azide-modified J591 scFv, conjugated to fluorescently 
labelled DBCO, in PSMA positive xenograft tumor with rapid renal clearance and shorter circulation 
time, which is more ideal for the application of imaging tracers.    
The novel bioconjugation methodologies described here have contributed to the bio-
nanomaterial research field, and have facilitated the creation of versatile antibody-nanoparticle 
conjugates, for the active targeting of bionanomaterials, as well as complex imaging contrast agents 
for in vivo diagnostic purposes. Furthermore, the utilizing of BsAbs presents a generic methodology 
for targeting drug-loaded nanomaterials to potentially any tumor-associated antigen.  Currently, our 
group are utilizing this BsAbs for targeting HBP to other prostate cancer cell biomarkers, such as 
glypican-1 (GPC-1) antigen. Our group is also demonstrating the potential benefit of incorporating 
azide-bearing UAA into anti-PSMA J591 scFv for bioconjugation into larger structures such as a 
DBCO-containing thermo-responsive PEG-based polymer in micellar systems. The conjugation 
strategies developed here show much promise for simplifying the production of antibody 
nanomaterial hybrids, for use in targeted in vivo cancer diagnosis and for therapeutic applications, 
advancing the field of precision nanomedicine.  
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Chapter 1 Introduction 
Nanotechnology has been intensively researched as a powerful tool to investigate novel 
strategies for addressing the unmet clinical challenges in the treatment of various diseases, principally 
cancer, and also in the advancement of diagnostic applications. Nanoparticles (NPs) as drug delivery 
systems have had a significant impact in improving therapeutic efficacy for cancer treatment in 
comparison to systemic drug delivery, through specific targeting and subsequently lowering overall 
drug dosage, resulting in reduced cytotoxicity effects [1]. Moreover, increasing cellular uptake can 
potentially be achieved by active cellular targeting, through cell-specific ligand conjugation to NPs. 
Numerous ligands, such as proteins (antibodies, antibody fragments, transferrin, and growth factors), 
peptides, aptamers, carbohydrates, nucleic acids, and small molecules have been widely explored for 
NP-mediated drug delivery [2, 3]. Among these ligands, monoclonal antibodies (mAbs) are widely 
utilized for targeting NPs, due to their highly specificity. Currently, there are around 80 mAbs 
approved and marketed globally [4]. Even so, there are no actively-targeted NPs approved for clinical 
use in the diagnosis and treatment of cancer; however there are currently some promising candidates 
in clinical development [5]. The research reported in this thesis is focused on the development of novel 
targeted nanomedicines using novel bioconjugation strategies to create antibody-nanomaterial 
conjugates, for the potential diagnosis and treatment of cancer.   
1.1 Antibody-nanomaterials conjugate 
Numerous ligands have been investigated for the active targeting of NPs for tumor therapy. 
The high selectivity of therapeutic mAbs makes them an ideal ligand for actively targeting 
nanomedicines.  Furthermore there are many mAbs under clinical development, creating an even 
greater number of potential targets for cancer treatments than exists at present [4].  
As therapeutic agents, mAbs have a variety of mechanism of actions for cancer treatment, 
including directly attacking cancer cells through various mechanisms, blocking regulators of the 
immune system, triggering cell membrane destruction and inhibiting cell growth. However, the use 
of antibodies has several limitations, including the potential for immunogenicity, down-regulation of 
target receptors [6], and antibody drug resistance [7]. On the other hand, although typically lacking 
cellular specificity, several features of NPs such as stable drug encapsulation, multiple drug loading, 
controlled drug release and longer systemic circulation, offer advantages as next-generation 
nanomedicines. The conjugation of NPs with antibodies can generate a product combining the 
properties of the NPs themselves with the ability of the antibodies to specifically recognize the target 
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antigen. Moreover, there are two main benefits of using antibody-nanomaterial conjugates, including 
the improvement in the cellular uptake and also intracellular stability [8] (Figure 1.1). 
 
 
Figure 1.1: Characteristic features of antibodies, NPs and antibody-NPs conjugates. The conjugation of antibody 
into NPs can generate a product combining both of properties of the NPs and the specificity of mAbs, improving cellular 
uptake as well as resulting intracellular stability.   Redrawn from Sivaram et al., 2017 [7].  
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It is understandable that the properties of targeting antibodies are modified once conjugated to NPs, 
including antigen-binding specificity and affinity which can impact the pharmacokinetic and 
pharmacodynamic profiles and the potential off-targeting of the antibody. However, the specific 
affinity (strength of the physico-chemical interaction with antigen) of an antibody may be not be as 
critical, since the multiplicity of epitopes on the surface on the NP creates an avidity effect, resulting 
in an overall increased apparent affinity. In term of site specific conjugation and control of orientation 
of mAbs on the surface of NPs, several techniques have been developed, such as introduction of 
reactive groups at specific amino acid residue sites in the mAb, to enable attachment to the NP surface 
[9].  The various strategies involved in the synthesis of this hybrid material are shown in Figure 1.2. 
Figure 1.2: Series of synthetic schemes showing various strategies for the developing antibody conjugated Nps. 
Adapted from Sivaram et al., 2017. Copyright Advanced Healthcare Materials [7]. 
1.2 Research aim and strategies 
Antibody targeted NPs have shown great promise in cancer therapy applications, with several 
potential candidates having been tested in clinical trials [10-13]. Creating an efficient and stable 
antibody-nanomaterial conjugate is important for the generation of a homogeneous product with 
defined function(s). Several methods have been developed for site-specific conjugation to obtain 
homogeneity of the final product as well as enhancing receptor-binding activity [14, 15].  Many of these 
methods such as traditional chemical conjugation approaches have many challenges associated with 
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the generation of antibody-nanomaterial conjugates. The methods are complex, inefficient, 
conjugation may occur at sites involved in binding activity and multiple reagents are required.  
The primary overarching aim of this study is to develop simple methodologies to get around 
challenges faced using other conjugation strategies, to facilitate stable bioconjugation of an antibody 
fragment to a NP, to create an actively targeted nanomedicine, for imaging and therapeutic 
applications.  In this study, we chose prostate cancer as a model disease. For receptor targeting, we 
utilize prostate specific membrane antigen (PSMA), since its expression is upregulated many fold in 
almost all prostate cancer stages, and can be related to tumor aggressiveness, metastatic disease and 
disease recurrence [16, 17], making this antigen an excellent target in prostate cancer detection and 
therapy. To target this receptor, we use J591 anti-PSMA antibody. Currently, this antibody is widely 
researched for prostate cancer treatment. A humanized version of J591 has been shown to be effective 
in imaging and delivering radionuclides, resulting in therapeutic responses in prostate cancer clinical 
trials [18-20]. 
The objective of this research is to develop novel bioconjugation strategies to rapidly and 
simply create hybrid antibody-nanomaterial formulations for application in diagnostics and as drug 
delivery tools.  In this study two bioconjugation strategies were developed including:   
1. A novel bispecific antibody (BsAb) platform technology. The BsAb exhibits dual
specificity for methoxy-PEG (mPEG) epitopes on HBP nanomaterials and prostate cancer
target PSMA receptor on cancer sites. The BsAb is mixed with fluorescence imaging dye-
labelled hyperbranched methoxy-PEG polymer (HBP) or Doxorubicin (Dox) loaded HBP
to obtain a homogenous bioconjugate.
2. A single chain antibody fragment targeting PSMA engineered with an azide group at a
specific protein site using unnatural amino acid (UAA) incorporation.  The azide UAA
enables site specific and precise click chemistry conjugation of the antibody with
cycloalkyne-containing fluorescent dyes or with polymer activated  cycloalkyne-
containing fluorescent dyes [21, 22].
To evaluate the suitability of these formulations as targeted nanocarriers, testing was required 
to be carried out, including protein characterization and confirmation of bioconjugation, as well as 
various in vitro and in vivo bioassays, namely:  
a. tumor cell uptake studies by flow cytometry and confocal microscopy,
b. in vitro cytotoxicity study in PSMA expressing prostate cancer cells,
c. biodistribution studies using animal imaging and tumor accumulation in xenograft mouse
models to verify in vivo localization of these conjugate formulations.
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 By generating two different conjugation methods of antibody-nanomaterial, we can determine 
the feasibility of using these formulations for efficient actively targeted nanomedicines for potential 
application in cancer diagnosis and therapy.  
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Chapter 2 Literature Review 
 
2.1 Targeting NPs 
 
 Over the past few decades, nanotechnology has been an emerging area, and has been applied 
to medicine for the treatment of diseases, especially in cancer medicine. The characteristic dimensions 
of the NP, which is in the size range 1-100 nm, can influence the physicochemical properties of the 
nanomaterials/nanomedicines. These properties can be employed for numerous practical applications, 
including diagnostics, imaging and drug delivery systems. Several nanocarriers have been extensively 
investigated for targeted delivery to increase therapeutic index in cancer treatment. Compared to 
traditional chemotherapy, targeted therapy utilizing encapsulated drugs in NPs is a promising method 
to enhance therapeutic efficacy while avoiding undesirable side effects for patients due to cytotoxic 
nature of anti-cancer agents [23]. NP encapsulation technologies are able to protect poorly soluble 
drugs [24, 25], and therapeutic molecules [26], resulting in stable formulations and favorable drug 
bioavailability. Nanotechnology-based formulations for chemotherapy drug delivery have been 
extensively employed and show superior pharmacokinetic properties and tumor site-specific delivery 
compared to those of conventional formulations. This nano-encapsulated drug circulates through the 
bloodstream and it is driven to the target tumor site for simultaneously in vivo drug release in a  
controlled manner. For some NPs, the size is big enough to be rapidly cleared in the kidney (<10 nm), 
but smaller than the size that can be recognized by the reticuloendothelial system (RES) organs (>200 
nm) [27]. In addition, multifunctional NPs, which have diagnosis/imaging and therapy capabilities in 
one single entity, (i.e.theranostics) are being developed to diagnose and treat cancer [28, 29]. This 
system offers the opportunity to delineate disease boundaries, monitor therapy in a real time and offer 
prognostic options [30-32]. 
 The first therapeutic NP used in clinical application was PEGylated liposomal Doxorubicin 
(Doxil®, Janssen Biotech, Inc. PA, USA) which received US Food Drug Administration (FDA) 
approval in 1995 for treating certain types of cancer (breast cancer, ovarian cancer, HIV associated 
Kaposi’s sarcoma  and other solid tumors). Following this, several therapeutic NP compositions based 
on liposomal formulation were approved by US FDA to treat various cancer, including Daunorubicin 
liposomal (DaunoXome® (Galen Limited, Craigavon, UK), Vincristine liposomal (Marqibo®, 
Spectrum Pharmaceuticals, NV, USA) and Irinotecan Liposomal (Onivyde®, Ipsen 
Biopharmaceuticals, NJ, USA). A non-liposomal NP was also approved by US FDA for clinical use, 
an albumin-bound Paclitaxel formulation Abraxane® (Abraxis BioScience, CA, USA for treating 
advanced non-small-cell lung cancer, metastatic pancreatic cancer, and metastatic breast cancer [33, 
34]. These therapeutic NPs utilize a passive targeting mechanism, taking advantage of leaky 
vasculature in tumor cells. The formation of new, irregular blood vessels in solid tumor, known as 
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angiogenesis, creates fenestrated capillaries, with gaps ranging from 200 to 2000 nm, depending on 
the tumor types as well as its environment and localization. In addition, the function of lymphatic 
drainage of tumors is also ineffective, allowing molecules smaller than 4 nm to diffuse back into the 
blood circulation, while larger molecules or NPs are retained and accumulate in the tumor. This 
process is known as the enhanced permeability and retention (EPR) effect which has been extensively 
investigated in the  systemic administration of cancer nanomedicines [35].  However, according to 
recent meta-analysis studies, less than 1% of administered NPs are accumulated in solid tumors. This 
could be due to multiple physiological barriers involved in extravasation of NP through the tumor 
vasculature [36]. Other studies report that a major proportion of NPs are potentially cleared by the 
mononuclear phagocytic system (MPS), and some are accumulated in the liver or taken up by 
hepatocytes and Kupffer cells [37, 38].  
 Understanding tumor biology is fundamental to overcoming this limitation. The tumor 
environment is very complex and heterogeneous, contributing the irregular tumor vasculature and 
congested tumor lymphatic that may restrict the entry and transport NPs. For example, the degree of 
leakiness of tumor vasculature will depend on many factors, such as type of tumor and its stage, 
different xenograft models or the different location of grafted tumor.  Moreover, since the first 
discovery of EPR effect by Matsumara and Maeda in 1986, investigations are mainly carried out in 
animal models, but are less well documented in humans, possibly due to the challenges in obtaining 
meaningful biodistribution data in human [35].  As a result, clinical outcomes of therapeutic NPs is 
highly heterogeneous with a high percentage failure rate, meaning that NP-mediated drug delivery 
will not always present the therapeutic benefits as anticipated in preclinical experiments [39]. 
Therefore, several studies have explored the strategies of tumor targeting utilizing the EPR effect to 
enhance patient responses [40]. 
 One of the strategies to overcome heterogeneity of EPR-based tumor targeting is utilizing 
ligand conjugated to the surface of NPs (Figure 2.1) [41]. Ligand-mediated targeting, also called active 
targeting, allows the NPs to bind specifically to cell surface receptors, facilitating internalization into 
the tumor cells via receptor-mediated endocytosis. This approach aims to enhance the accumulation 
of NPs and internalization of drugs into target tumor cells. Numerous targeting molecules have been 
used for functionalization of NPs including antibodies, affibodies, aptamers, peptides, sugars, and 
small molecule receptor ligands. Currently, it is proposed that active targeting of NPs complements 
the EPR effect, resulting in better therapeutic outcomes with fewer off-target effects [9, 35, 40].    
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Figure 2.1: Schematic passive and active targeting NPs in solid tumor. Adapted from Peer et al., 2017 [41]. Passive 
targeting is achieved by utilizing EPR effect, taking the advantage of leaky vasculature and ineffective lymphatic drainage 
in tumor cells. In active cellular targeting, functionalization of NPs promotes the recognition and specific binding into 
target cells, whereas, (i) the carrier may release the cargo in tumor vicinity; (ii) attach to membrane cells and release the 
payload in a sustained manner, or (iii) cellular internalization via receptor binding endocytosis.  
   
 The attachment of ligands onto NPs can influence the properties of both NPs and targeting 
ligands. Ligand molecules can lose the translational and rotational freedom, while the geometry or 
size of NPs can also be altered. Therefore, it is crucial to determine the physicochemical properties 
of those molecules for targeting efficiency. For example, the consideration of NP size and shape can 
affect their blood circulation, cellular uptake and tumor accumulation. In addition, surface charge and 
hydrophobicity might also possibly affect their interaction with the target cells. The density of ligand 
on NPs also influences their affinity and maximal cellular uptake into target cancer cells. Lastly, 
choosing the right ligand molecule is a critical aspect for targeting efficiency (Figure 2.2)[35].  There 
are a variety of mAbs that have been identified for the targeting of biomarkers identified or associated 
with cancer as well as being used as stand-alone therapeutics.  The simple, stable and efficient 
conjugation of mAbs and antibody fragments to NPs is critical for optimal active targeting of cancer. 
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Figure 2.2: The physicochemical properties of the targeting ligands and NPs which can affect the blood circulation, 
biodistribution, and cellular uptake and internalization by tumor cells. Adapted from Bertrand et al., 2014 [35]. 
2.2 Conjugation strategies for targeting of mAbs into Nps 
The stable conjugation of mAbs to NPs is a key for successful targeting. In general, the 
conjugation of mAbs to NPs can be achieved through three different approaches, including through 
physical adsorption, covalent conjugation, and adaptor biomolecules. Table 2.1 outlines currently 
used bioconjugation strategies, including the summary of benefits and drawbacks of each strategy. 
These strategies are discussed in more details within the following sections. 
I. Conjugation via physical adsorption
Numerous physical adsorption methods have been proposed to couple mAbs with several
types of NPs. This method is one of the simplest ways to synthesise bioconjugates, mainly
based on the physical interactions, such as hydrophobic interactions, electrostatic adsorption,
and  hydrogen binding or van der Waals forces of attractions [42]. It is a direct conjugation
method, combining two components without any chemical modification. Research reported
this non-specific interaction can obtain good results in terms of the orientation of antibodies.
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However, several disadvantages arise such as poor reproducibility and low stability in 
different pH conditions (pH dependent) [43].  
II. Conjugation via covalent binding
Chemical approaches via covalent attachment of mAbs to NPs is the most common method
for synthesis of bio-nano conjugates and a good technique to overcome the drawbacks of
physical conjugations. Numerous  reactive groups on amino acids can facilitate conjugation
reaction, such as lysine (amine group), glutamic and aspartic acid (carboxyl group), and
cysteine (via reduction of cysteine), as well as the carbohydrate moiety of mAbs (via periodate
oxidation of cis-diols to aldehydes). In addition, the reactive groups can also be introduced to
NPs, either via adsorption, by covalent linkage, or due to inherent nature of the NPs, such as
bifunctional thiol in gold NPs [9].
a. Amide bond formation
The amide bond is typically a stable linkage, can be formed via NHS activated group on
the nanomaterial with the amine group on the antibody [44]. Another strategy utilizes
carbodiimide as a crosslinking agent resulting a stable amide bond between the amino
group of protein and carboxyl group on the NP surface [45].
b. Disulfide/thioether formation
Thiol groups on mAb or NP can react with a maleimide group or a pyridylthio group to
form thioether or a disulfide bond, respectively. A thiol group introduced into mAbs either
using heterobifunctional reagents or the reduction of disulphide bonds of intact mAb can
be directly conjugated to the surface of gold NPs [46]. Another example links thiolated
mAbs with maleimide functionalized lipid on lipidic NPs, with a conjugation  efficiency
up to 99% while only slightly reducing antibody binding affinity [47]. In general, thiol-
coupling chemistries are versatile for bioconjugation methods under mild conditions;
however, there are several investigations that report an unstable reaction using this
coupling method. Numerous approaches have been investigated to overcome this issue,
such as utilizing both thiol groups within a dithiobridge in the native antibody. This
approach can preserve the protein structure, and result in a quick and efficient coupling of
mAbs to NPs [7].
c. Sugar moieties
Carbohydrate residues in the hinge region of mAbs can be utilized for site-specific
conjugation to NPs, and offers an advantage, whereby the antibody is specifically
orientated on the NP at a site distant from the antibody-binding site. This coupling reaction
can be achieved through several ways. For example, oxidation of polysaccharide moieties
of Fc region for bioconjugation into magnetic NPs [7]. Another oxidation reaction is
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through the hydroxyl group of sialic acid or mannose which results in aldehyde residues 
that can be modified to form hydrazone. These modified mAbs can be directly linked with 
gold nanorods [9].  
d. Click chemistry
The click reaction is one of the most promising covalent conjugation strategies and
involves the formation of a stable and inert triazole linkage, combining an azide and an
alkyne molecule. This reaction is fast and simple to use, versatile, highly stereospecific,
and provide high product yields. As a consequence, it is widely applied in variety of
research areas, such as in polymer chemistry, material sciences, and pharmaceutical
sciences [48]. The concept was originally introduced by Sharpless in 2001 [49], using the
copper I (Cu(I)) catalyzed alkyne–azide cycloaddition (CuAAC) to synthesize 1,2,3-
triazole derivatives under mild conditions, which is one of the most applied among other
click reactions [50]. Finneti and colleagues developed an alkyne-functionalized polymer to
coat gold NPs, and were subsequently conjugated with azido-modified anti-CD63 mouse
antibody through CuAAC click reaction [51]. However, the Cu(I) catalyst is readily
oxidized, and it can interact with biomolecules which is related to toxicity. Some strategies
have been employed to minimise the side effects of Cu(I) catalyst in click chemistry
reaction, including the use of reducing agents (e.g. sodium  ascorbate, hydrazine and
hydroxylamine) to prevent the oxidation [52], and complexing the Cu using a chelator ( e.g
(tris[(4-carboxyl-1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine)) to minimize toxicity
issues [53]. As an alternative, Cu-free strain promoted azide-alkyne click (SPAAC)
chemistry reaction was developed in 2004, utilizing cyclooctynes and azide in the absence
of catalyst, and can be done under mild conditions [54].  Dibenzocyclooctyne (DBCO) and
bicycle [6.1.0] nonyne (BCN) are representative of cyclooctyne which can be attributed
either into mAbs or polymer.  Jeong et al. reported the cyclooctyne functionalized anti
Her-2 IgG attached in Fc region was successfully conjugated with azide-functionalized-
silica-encapsulated NPs showing orientation control of antibody with high conjugation
efficiency. Furthermore, this strategy has strong binding capability of antibody conjugated
NPs, which was 8 times higher compared to EDCI/NHS coupling method [55]. The third
generation of click-chemistry reaction has been proposed using Diels–Alder cycloaddition
between a trans-cyclooctene and tetrazines. This method provides a faster reaction rate
compared to the other two previous methods [56].
III. Conjugation via adaptor biomolecules
The various strategies of covalent conjugation described above are generally non-site specific, 
 resulting in sub-optimal orientation of antibody on the NP surface which can alleviate binding
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efficiency, and may lead to aggregate formation. Non-covalent binding reactions using 
adaptor biomolecules presents a strategy to overcome these limitations. One of the most robust 
and extremely rapid strategies is through biotin-binding protein. Antibody is typically 
modified with biotin, and subsequently conjugated to streptavidin-modified NPs [57]. This non-
covalent strategy has high-affinity interaction (KD ~1015) with numerous  studies showing 
the stability of antibody-NP conjugate. For example, biotin (AviTag labelling) introduced into 
scFv targeting endothelial cells of blood brain barrier (BBB), was successfully incorporated 
into streptavidin modified quantum dots. This conjugate was fully internalized into BBB 
endothelial cells [58]. This strategy, however, will depend on the amount of biotinylated mAbs 
which can limit the interaction with avidin-modified NPs. To overcome this deficiency, 
antibody-conjugated NPs can be achieved by utilizing Fc-binding proteins, which can interact 
with the Fc region, leaving the Fab region as antibody-binding site fully active. Several Fc-
binding proteins, including Protein A, Protein G, Protein A/G, and FcγR that were 
incorporated into NPs, were successfully conjugated into immunoglobulin of interest [59]. The 
secondary antibodies were also used for antibody-NPs conjugate, utilizing anti-polymer 
antibodies, which were incorporated into antigen-target antibody through bispecific design. 
Research claimed that these strategies offer the highly specific and stable conjugation, 
yielding homogeneity product [60-62]. 
Another promising technique is using nucleic acid hybridization strategy, incorporating a 
complimentary single-strand sequence into both antibody and NP. The coupling reaction was 
then achieved via that complimentary pairing. This hybrid has potential for cellular 
transfection and gene knockdown; however, as such structure typically exhibits cell type 
selectivity [63].  
 Enzyme-based conjugation is also utilized to overcome the limitation of chemistry 
conjugation. Sortase A, a Staphylococcus aureus transpeptidase, is an enzyme which 
specifically recognizes the leucine-proline-glutamic acid-threonine-glycine (LPETG) peptide 
motif and cleaves between the threonine and glycine residues forming a new amide bond, and 
subsequently bind into N-terminal glycine of other biomolecules. Leung et al. used this 
strategy for targeted imaging approach, involved the fusion of sortase A into anti-platelet scFv 
that was successfully coupled into polymeric system containing azide functionalized-alkyne 
modified PEG and poly(N-vinyl pyrrolidone) through azide-modified triglycine-containing 
peptide. This bio-click chemistry reaction offer a means to produce bioconjugate with a 
controlled and defined orientation of antibody  compared to CuAAC reaction [14]. 
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Table 2.1 Different strategies for the synthesis of antibody-NP conjugates: advantages and disadvantages. Adapted 
from Sivaram, et al., 2017 [7].     
Strategy Functional groups 
involved 
Advantages Disadvantages Ref. 
Physical Adsorption  
Hydrophobic 
interactions 
Hydrophobicity Simple coupling 
mechanism 
Change in 3D confirmation, 
resulting in Ab denaturation; 
lack of specificity 
; poor reproducibility 
[64-66] 
Electrostatic 
adsorption 
Charged groups Doesn’t require 
activation of antibodies 
and NPs; quick 
interaction 
 
Depends highly on the 
environment and the 
availability of charged groups; 
interactions are highly pH 
dependent; varies with respect 
to physical properties of NP 
[67, 68] 
Hydrogen bonding Groups with H- 
bond donor and 
acceptor 
Facile, versatile, no need 
to modify the antibody 
Reversible attachment; poor 
reproducibility 
[69, 70] 
Covalent binding  
EDC-NHS amide 
bond 
Primary amine on 
antibody; 
Carboxylic and 
epoxide groups on 
NPs 
Native antibodies can be 
used; highly efficient 
 
Involves multiple steps; 
chemical modification of NPs; 
active sites of antibodies can 
interact with NPs and cause 
less chance of antigen binding; 
loss of the reactive moieties 
with other interactions 
[71-74] 
 
 
 
 
 
 
 
Disulfide 
functional groups 
/maleimide thiol 
coupling   
Disulfide group; 
Thiol group; 
Sulfhydryl group 
 
High stability; better 
ligand positioning 
 
Chemical modification of the 
antibodies 
 
[75-79] 
Sugar moieties Gold surface; Thiol 
reactive group; 
Hydrazide group; 
Amine group; 
Piridyl group 
Oriented binding; Better 
Specificity; Highest 
retention of antigen 
binding capacity 
  
Antibodies needs to be 
modified to interact with NPs; 
sugar moieties won’t be 
available for conjugation 
    [80-82] 
 
 
Click chemistry 
(Cu assisted) 
 
 
 
 
 
 
 
 
 
Click chemistry 
(Cu free) 
(Bioorthogonal 
click chemistry 
Azide group; 
Alkyne group; 
Tetrazine and 
Trans-cyclooctene 
component 
 
 
 
 
 
 
Azide group 
DBCO group 
Mostly oriented binding; 
Strong binding; Quick 
interaction; Better yield 
even at room 
temperature; Zero By-
products 
 
 
 
 
Mostly oriented binding; 
strong binding; quick 
interaction; better yield 
even at room 
Presence of copper (Cu) 
catalyst can results in 
instability of protein; copper 
catalyst hinders the 
fluorescence of the dyes; 
toxicity issues with copper 
catalyst requires Cu chelators 
to minimize toxicity; require 
modification of the Ab with 
the linker group 
 
Require modification of the 
Ab with linker group 
[83-87] 
 
 
 
 
 
 
 
 
 
 
[88-90] 
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Tetrazine and 
trans-cyclooctene 
component 
temperature; zero by-
products 
Adaptor biomolecules 
Biotin-binding 
proteins 
Biotin; Streptavidin; 
Avidin; NeutrAvidin 
Mostly oriented binding; 
Highly stable interaction; 
Resistant to varying 
external factors. 
Expensive; Difficult to control 
NP valency; difficult to 
control the binding site; 
labelling can be heterogeneous 
[91-94] 
Secondary 
antibodies 
Anti-PEG antibodies Easy to control NP 
valency; Ab remains 
unaffected 
Reversible binding; 
orientation highly depend on 
the secondary antibodies; 
Secondary antibody must be 
monoclonal and it is expensive 
[60, 62] 
Fc binding proteins Protein A: Protein G; 
Protein A/G 
Ab remains unaffected Difficult to control NP 
valency; Fc binding proteins 
(A,G) are expensive: 
Reversible binding 
[95-98] 
Nucleic acid 
hybridization 
Oligonucleotide 
sequences 
Highly specific 
complementary base 
pairing; ideal for 
biosensor application 
Orientation highly depend on 
the nucleic acids; difficult to 
control ligand orientation on 
NP surface 
[99-103] 
Enzyme based bio-
conjugation  
Sortase A enzyme Precise control over 
conjugation; mild 
reaction condition 
Coupling limited by the large 
size fusion protein; multiple 
preparation steps 
[104] 
2.3 Cancer biomarkers as a receptor target for cancer therapy 
Typically, cancer cell therapeutics and in particular mAbs, target various membrane-
associated proteins that include CD19, CD20, EGFR, PDL1 and others. The differential expression 
of membrane proteins on cancer cells defines the phenotype, and over the past few decades, many 
membrane-associated proteins have been investigated as potential targets for cancer therapy. These 
proteins, spanning the cell membrane (transmembrane or integral membrane proteins), or on the 
surface of the membrane (peripheral membrane proteins), are involved in the regulation of cancer cell 
formation, and have been extensively studied as cancer prognosis/diagnosis biomarkers and applied 
to targeted imaging and therapeutic applications. [105-107]. In general, the expression of membrane 
proteins is upregulated in tumor and tumor associated cells, including in malignant and angiogenetic 
cells [108], which can be discriminated from normal, healthy cells of tissues.  Based on their biological 
function, there are at least 5 classifications of membrane-bound protein, including receptors (tyrosine 
kinase receptor (TKR) and G-protein coupled receptor (GPCR)), cell adhesion or anchoring proteins, 
cell membrane-associated enzymes, transporter proteins, and glycosylphosphatidyl inositol (GPI) 
proteins [106].  Several membrane-associated proteins have been widely studied as cancer biomarkers 
and disease targets, and numerous clinical applications have been reported, with treatment of breast, 
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lung and prostate cancer being the most prevalent, and combined, make up the majority of cancer 
related mortality (Table. 2.2). The research reported in this thesis is associated with the targeting of 
antibody-nanomaterial conjugates to the prostate specific membrane antigen which is overexpressed 
in prostate cancer. 
Table 2.2 Characteristic of membrane-associated proteins as cancer antigen. 
Protein Role in Cancer Clinical applications Ref. 
Tyrosine kinase receptors 
EGFR 
(ErbB-1) 
Colorectal, 
Non-small cell lung 
cancer 
Uncontrolled cell 
proliferation, and 
metastasis 
Cetuximab, Panitumumab, 
Necitumumab 
[109, 110] 
HER-2 (ErbB-2) Breast, Gastric, 
Esophaegal, Ovarian 
Cellular proliferation 
and differentiation 
Trastuzumab, Pertuzumab, 
Neratinib, Lapatinib, Afatinib 
[111, 112] 
EphA2 Solid tumors Metastasis and poor 
clinical prognosis 
Anti-EphA2(1C1)-auristatin drug 
(toxin) conjugate; Dasatinib, 
synthetic small molecule inhibitor, 
binds to EphA2 
[113-115] 
VEGFR Colorectal Angiogenesis Bevacizumab, Ramicrumab [116, 117] 
cMET /HGFR 
Lung Cellular proliferation, 
metastasis, invasion, 
angiogenesis, and cell 
motility  
Rilotumumab, Onartuzumab, 
Ficlatuzumab 
[118-120] 
IGF-1R Solid tumors Cellular proliferation, 
invasion and 
angiogenesis 
Cixutumumab, Figitumumab [121-123] 
GPCR 
Chemokine 
receptor, CXCR-4 
Multiple Myeloma 
and Lymphoma 
Distant metastasis, 
angiogenesis, and 
therapeutic resistance 
68Ga-Pentixafor [124, 125] 
Cell adhesion molecules 
CEA Colon Tumor invasion and 
metastases 
Labetuzumab [126, 127] 
EpCAM Colon Cell signaling, 
proliferation and 
differentiation 
Adecatumumab, Catumaxomab [128-130] 
αvβ3 integrin Endothelium Tumor invasion, 
angiogenesis, and 
metastases 
Etaracizumab [131, 132] 
Cell membrane associated enzymes 
PSMA Prostate unclear Capromab, J591 [133] 
CD13 Macrophage Intracellular signaling - [134] 
CAIX Colon Regulator of pH Girentuximab [135, 136] 
GPI-anchored proteins 
Mesothelin Mesothelioma Peritoneal 
implantation, and 
metastasis 
Amatuximab [137] 
PSCA Prostate, Pancreatic unclear AGS-1C4D4 [138] 
uPAR Colon cell adhesion, 
migration and 
proliferation 
ATN-658 [139] 
Folate receptor Ovary DNA synthesis, 
methylation, and 
repair 
Farletuzumab [140] 
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2.3.1 Prostate specific membrane antigen (PSMA) 
The overriding rationale for choosing and utilizing a membrane-bound protein as a target for 
cancer imaging and therapy, is the significant over-expression of that particular membrane bound 
protein in neoplastic growth compared to that in normal tissue. In prostate cancer disease, for 
example, several antigens are overexpressed, including PSMA, the epithelial cell adhesion molecule 
(EpCAM), ephrin type-A receptor 2 (EphA2) and the vascular endothelial growth factor (VEGF), all 
having potential as prognostic biomarkers in prostate cancer [141-144]. Among these antigens, PSMA 
has been demonstrated to be an ideal prognostic marker since PSMA expression is upregulated many 
fold in almost all prostate cancer stages, including tumor aggressiveness, metastatic disease and 
disease recurrence, but has a low expression in normal healthy tissues [16, 17, 145-147]. 
PSMA, known as glutamate carboxypeptidase II, or folate hydrolase 1 (FOLH1), is a type II 
transmembrane glycoprotein containing 750 amino acids, with MW around 100 kDa. PSMA has 
enzymatic activity, serving as transport or binding proteins or have hydrolytic activity [148]. PSMA is 
not only expressed in prostate tissues, but is also found at lower levels in other tissues, such as kidney, 
liver, small intestine, and brain [133, 149]. The PSMA protein has a unique 3-part structure, including 
an N-terminal internal portion (19-amino-acid), a transmembrane portion (24-amino-acid), and an 
external portion (707-amino-acid) [146, 150].  This large external portion, known as the extracellular 
domain of PSMA contains proline- and lysine rich domains with unknown function, a large catalytic 
domain, and a C-terminal domain. This domain has nine N-linked glycosylation sites, which are 
required for secretion of the cleavable extracellular domain, membrane expression and enzymatic 
activity [151, 152]. 
To date, numerous ligands including small molecules, antibodies, and antibody fragments 
targeting PSMA have been generated and radiolabeled for therapeutic use. These PSMA ligands are 
currently being used and investigated in pre-clinical and clinical studies for prostate cancer imaging 
and therapy [153]. For example, 111In-capromab-pendetide has been approved by US FDA for imaging 
soft tissue metastatic prostate cancer. Other radiolabeled PSMA ligands are being studied in phase II 
and III clinical trials as theranostics (combining diagnostic and therapy), such as 68Ga-PSMA-PET, 
177Lu-PSMA-617, and 177Lu-anti PSMA J591 [154].  
In this study, two different bioconjugation methods including BsAb platform technology and 
unnatural amino acid azide labelling will be used to tether anti-PSMA antibody fragments to 
nanomaterials for application in diagnostics, in vivo imaging and potential therapeutic delivery to 
prostate cancer tumors. 
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Chapter 3 Non-covalent conjugation of an anti-PSMA antibody to a hyperbranched PEG 
polymer using bispecific antibodies as precision nanomedicine for prostate cancer  
 
3.1 Introduction 
  
Antibodies have the capability to bind with high specificity to specific antigens, which makes them 
ideal reagents for biomedical research applications. As tools, numerous applications of antibodies 
have been widely reported and utilized in biomedical research, as secondary antibodies conjugated to 
enzymes or fluorophores for the purpose of detection of specific molecular entities, such as in 
immunohistochemistry, Western blot, immunocytochemistry, flow cytometry and ELISA [155-157]. In 
addition, antibodies are highly effective as therapeutic and in vivo diagnostic agents, and are utilized 
extensively in cancer medicine. They can be used as naked antibodies for therapeutic applications, 
taking advantage of immune effector function such as Antibody Dependent Cellular Cytotoxicity 
(ADCC) and Compliment Dependent Cytotoxicity (CDC), or they can be coupled with other different 
molecules, such as radioisotopes, chemotherapeutic drugs, nanomaterials, and fluorescent agents, that 
impart targeted imaging and cytotoxic capability [158]. 
Bispecific antibodies (BsAbs), also called ‘dual targeting antibodies’ have recently come to 
the attention of the global scientific community for development of diagnostic and therapeutic 
applications in cancer treatment [159]. BsAbs were discovered in the 1960s when the two different 
antigen-binding fragments (Fabs) of polyclonal sera were conjugated to make bispecific F(ab’)2 
molecule [160]. However, the first approved BsAb is Catumaxomab, a trifunctional antibody 
combining EpCAM antigen, CD3 antigen for T-cell and an Fc portion for the recruitment of immune 
cells and received regulatory approval by European Medicine Agency (EMA) in 2009.  
Catumaxomab has an orphan drug status from FDA for the treatment of malignant ascites. In 2014, 
another BsAb, blinatumomab, was approved by FDA.  Blinatumomab is a bispecific T cell engager 
(BiTE), comprising two scFvs, whereby one arm binds to antigen CD19, while the other arm targets 
CD3, which redirects and potently activates T cells. This BsAb is prescribed for the treatment 
relapsed or refractory (R/R) precursor B‐cell acute lymphoblastic leukemia (ALL) in adults and 
children [161].    
 The introduction and approval of BsAbs in the global market place has generated much 
attention and research activity within academia and industry, and the bioengineering of BsAbs has 
led to many candidate BsAbs entering clinical trials globally [162, 163]. In general, recombinant BsAbs 
can be differentiated based on the format and composition, including the presence or absence of Fc 
domain, symmetric or asymmetric architecture, and the number of binding sites [164]. A number of 
methods for the generation of BsAbs have been developed, including via chemical conjugation and 
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covalent attachment of fragments, genetic (protein or cellular) engineering, and through somatic 
fusion of two hybridoma lines (quadroma) [165]. Clinical applications of BsAbs are mainly for cancer 
therapy. Redirecting immune effector cells, such as T cells to tumor cells is common function for 
various designs of BsAbs, and as mentioned includes the clinically approved BsAbs using triomab 
(catuxomab) and BiTes (blinatumomab). Another BsAb design for the purpose of retargeting T cells 
to tumor cells is the Dual-affinity retargeting molecule (DART). The DART technology improves the 
stability of BsAbs and may decrease immunogenicity. Aside from T cell engagement, other strategies 
for engaging immune cells have been investigated, including the use of BsAbs to engage macrophage, 
monocytes and NK for the killing of tumor cells [166].  
 With multiple targeting sites within one single therapeutic entity, BsAbs also have significant 
potential for the treatment of other disease indications, including allergic, infectious and 
inflammatory diseases. BsAbs also have significant potential to be included in diagnostic 
applications, and have already been developed for detection of infectious diseases caused by bacterial 
and viral infections, as well as different types of cancers [159, 166]. 
 In a new, novel area of application, BsAbs have recently been utilized for the creation of 
antibody-targeted NPs [167, 168]. In another example, our group at AIBN has developed a novel 
methodology of BsAbs for targeting NPs to tumor cells through non- covalent conjugation. One arm 
of the BsAb binds the NP material, while the other targets membrane-bound, tumor associated 
antigens.  One example is the targeting of a bacterially derived NP with a BsAb with the dual targeting 
capability for lipopolysaccharide (LPS) and anti-epidermal growth factor receptor (EGFR).  In this 
system, the NP, termed the Engeneic Delivery Vehicle (EDVTM) is naturally coated with LPS.  These 
nuclear NPs of approximately 400 nm in diameter, can be loaded with drugs such as doxorubicin, and 
injected systemically for the treatment of solid tumors.  The EDVsTM can be actively targeted to tumor 
cells by mixing with a BsAb preparation that targets EGFR and LPS [61]. In this way the EDVTM is 
coated with BsAb and imparts EGFR functionality. 
 A simple and rapid method of conjugating antibody to NP has been developed using one-step 
mixing of mPEG NPs with BsAb containing a fusion Fab fragment of humanized anti-mPEG into 
scFv with specificity to the EGFR/HER2 tumor antigens utilizing 15 amino acids flexible linker 
((G4S)3). The methoxyl group in mPEG NPs participates in binding activity of anti-mPEG Fab 
fragment obtaining homogeneity product since no chemical conjugation step in this process. This 
simple and rapid method is also interchangeability, which is can be applied for other target receptors 
[62, 169]. Our group at AIBN has also developed the similar technique as a novel methodology for 
targeting PEGylated NPs to tumor cells. This non-chemical conjugation system has been reported 
utilizing an anti-EGFR and anti-mPEG scFvs joined with G4S flexible linker and PEGylated NPs. It 
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was also demonstrated that utilizing hyperbranched mPEG results in stronger binding of BsAbs 
compared to that of linear mPEG due to avidity effects [170]. 
 Herein we established the utility of a BsAb (tandem scFv consisting of anti-PSMA and anti-
mPEG scFvs), and PEGylated NPs made of hyperbranched mPEG polymer (HBP) as an actively 
targeted nanomedicine for the potential diagnosis and treatment prostate cancer. PSMA has been 
extensively investigated as a target for prostate cancer and has shown to be a promising target for 
tumor imaging and therapy. Until now, there is only one clinical agent targeting PSMA approved by 
the US FDA for identification of metastatic prostate cancer, utilizing antibody-radiolabeled, 7E11-
C5 mAb-111In conjugate, called ProstaScint®.  However, this conjugate has a limitation due to the 
mAb only binding the intracellular domain of PSMA. Thus, only cells with damaged membrane, such 
as necrotic cancer cells will bind 7E11-C5[171]. 
 Several mAbs have been reported to bind extracellular epitopes of PSMA including J591, 
D2B, 3C6 and 3/A12 which are widely utilized in research associated with prostate cancer imaging 
[172-175]. However, to date, only the J591 mAb has progressed to clinical trials. J591 mAb targets an 
extracellular domain of PSMA and binds to the majority of the apical domain, which is highly 
exposed and accessible. As a result, this antibody binds with high affinity to PSMA receptor [176]. In 
addition, a humanized version of J591 has been shown to be effective in imaging and delivering 
radionuclides resulting in therapeutic responses in prostate cancer in early phase 2 clinical trials [19, 
177, 178].  
 In this study, we utilize J591 mAb as a ligand for targeting nanomaterials to PSMA receptor 
in prostate cancer, in the continuing development of useful targeted nanomedicines. We produced a 
BsAb by creating a tandem scFv consisting of the J591 scFv fused with an anti mPEG scFv by a G4S 
linker.  The BsAb was mixed with a PEGylated NP (made of mPEG HBP), labelled with dye for 
detection and loaded with the cytotoxic drug doxorubicin. This study evaluated the capability of this 
BsAb to actively target PEGylated NPs to PSMA.  To investigate this capability, in vitro targeting 
efficiency, cellular uptake and in vitro cytotoxicity were studied, as well as the optimal molar ratio 
of BsAb:HBP.   
 
3.2 Materials and methods 
 
3.2.1 Hyperbranched polymer 
  
The hyperbranched polymers (HBP) used in this study was kindly provided by Professor 
Kristofer Thurecht (AIBN, UQ).  The HBP was synthesized using protocols as described in Howard 
et al. [60] for Cy5-labelled HBP and  in Pearce et al. [179] for Doxorubicin-loaded HBP. 
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3.2.2 Cell lines  
 
 Human prostate cancer cell lines, PC3 (ATCC CRL-1435) which is PSMA negative cell;  
LNCaP (ATCC CRL-1740) and PC3-PIP (PC3 transfected with human PSMA) which are PSMA  
positive cells, were cultured in RPMI 1640 (Gibco) containing 10 % fetal bovine serum (Gibco). All 
cells were incubated at 37 °C in 5% CO2.  
 
3.2.3 Cloning and protein expression of anti PSMA J591-mPEG BsAbs  
 
 The BsAb sequences were synthesized and codon optimized for mammalian expression 
system by Geneart. Anti mPEG scFv [180]  was incorporated with an anti-human PSMA J591 scFv 
comprising heavy chain variable region (GenBank: CCA78124.1) and kappa light chain variable 
region (GenBank: CCA78125.1) with flexible linker (G4S)3. A 6x Histidine and c-myc tags were 
incorporated at the N- and C-terminus respectively to facilitate purification as well as detection 
(Appendix A, Figure A.1) as described in Taylor et al. [61]. The optimized codon synthetic gene was 
cloned into a mammalian expression vector (NBF-347, National Biologics Facility) using HindIII 
and NotI restriction sites. The positive recombinant plasmid was expressed in a mammalian 
expression system using Chinese Hamster Ovary (CHO) cells. The CHO- XL99 which are adapted 
suspension cells from the attached CHO-K1 cell line (ATCC) was cultured in CD CHO medium with 
8 mM GlutaMAXTM (Gibco) at 37 °C, 7.5% CO2, with shaking at 125 rpm. On the day of transfection, 
the cells were prepared at 3x106 cells/ml using dilution with fresh medium. The transient transfection 
was performed as the following: plasmid DNA (2 µg/mL) was diluted in OptiPro serum free media 
(Gibco) (12.5% total volume). Concurrently, the PEIpro (Polypus-transfection) (8 µg/mL) were also 
diluted in OptiPro serum free media (Gibco) (12.5% total volume), and incubated for 30-60 sec. The 
two solutions then were mixed by pipetting and incubated for 15 min at room temperature without 
disruption. The DNA-PEI complex then were added into the culture in a shake-flask and gently 
swirled. The culture was incubated at 37 °C, 7.5% CO2, and shaking at  125 rpm for 4 to 6 h. Following 
this incubation, the culture was diluted in the fresh CD CHO medium with 8 mM GlutaMAXTM at 
ratio 1:2 (v/v) containing 7.5% Efficient Feed A and B (Gibco) (v/v), and 0.4% anti-clumping agent 
(Gibco). The culture incubation was then continued at 32 °C, 7.5% CO2, and shaking at 130 rpm for 
13 days. The culture was then harvested by centrifugation at 4750xg for 10 min. Following this, the 
BsAb expression in CHO cells was evaluated using western blot analysis. Briefly, the supernatant 
was loaded into precast polyacrylamide gels NuPAGE™ 4-12% Bis-Tris protein gels (Invitrogen). 
The protein sample was run in 1x MES buffer (Invitrogen) for 35 min, 200 V, then semi-dry 
transferred into PVDF membrane (Biorad). The membrane was blocked in blocking solution 
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containing 2% milk in 1xPBST (0.05% Tween-20 in 1X phosphate buffer saline (PBS)) for 30 min, 
and was then incubated with anti-cMyc-HRP antibody (Miltenyi Biotec) diluted 1/5000 in blocking 
solution for 1 h at 4° C. The membrane was washed 3 times in PBST solution, and then soaked with 
ECL substrate (Novex™). The protein band was detected using the Chemidoc imaging system 
(Biorad). 
3.2.4 Protein purification 
The supernatants were filtered through 0.22 µm PES membrane (Millipore) then applied onto 
HisTrap excel column (GE Healthcare).  The column was equilibrated with phosphate buffer 
containing 20 mM sodium phosphate, 500 mM NaCl pH 7.4. The BsAb supernatants were then loaded 
to the column, followed by washing using the buffer and eluting with the buffer containing 500 mM 
imidazole. The His eluate fraction was then buffer exchanged into 20 mM sodium phosphate, 500 
mM NaCl pH 7.4 to remove imidazole using HiPrep 26/10 column (GE Healthcare). The purified 
protein was then separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) using Bolt 4-12% Bis-Tris Plus gels (Invitogen) and protein purity evaluated by coomassie 
blue staining of proteins (InvitrogenTM NovexTM SimplyBlueTM SafeStain). 
3.2.5 Protein Characterization 
Size exclusion chromatography (SEC) was performed by applying 500 µL of sample into 
Superdex 200 10/300 GL (GE Healthcare) column equilibrated in 1x PBS with 20% Ethanol, and 
connected to AKTA purification system. The purification system was run using the flow rate of 0.5 
ml/min. The size distribution profile of the purified BsAb was also evaluated using dynamic light 
scattering (DLS) technique (DynaPro®Plate Reader, Wyatt Technology). 30 µl of 1 mg/mL BsAb 
was used for analysis.  
In addition, the identification of BsAb was examined using peptide mass fingerprinting (Mass 
Spectrometry Facility, School of Chemistry and Molecular Bioscience (SCMB), UQ). Briefly, the 
trypsinized and zip tipped samples (standard protocol at Mass Spectrometry Facility, SCMB UQ, Dr 
Amanda Nouwens) were separated using reversed-phase chromatography on a Dionex Ultimate 3000 
RSLC nano-system. Using a flow rate of 30 µl/min, samples were desalted on a Thermo PepMap 100 
C18 trap (0.3 x 5 mm, 5 µm) for 5 min, followed by separation on a Vydac Everest C18 column (150 
mm x 75 µm, 5um) at a flow rate of 300 nL/min. A gradient of 5-60% buffer B over 35 min where 
buffer A = 1 % ACN / 0.1% FA and buffer B = 80% ACN / 0.1% FA was used to separate peptides. 
Eluted peptides were directly analyzed on an Orbitrap Elite mass spectrometer (Thermo) using an 
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NSI electrospray interface. Source parameters included a capillary temperature of 275° C; S-Lens RF 
level at 63%; source voltage of 2.4 kV and maximum injection times of 200 ms for MS and 150 ms 
for MS2. Instrument parameters included an FTMS scan across m/z range 350-1800 at 30,000 
resolution followed by information dependent acquisition of the top 10 peptides in the ion trap. 
Dynamic ion exclusion was employed using a 15 second interval. Charge state screening was enabled 
with rejection of +1 charged ions and monoisotopic precursor selection enabled. The protein 
identification was then performed using ProteinPilot™ Software 5.0.1 (Sciex). 
3.2.6 Target binding ELISA 
The target binding of the J591-mPEG BsAb was evaluated by indirect ELISA (enzyme linked 
immunosorbent assay) methods using recombinant human (rHu) PSMA as target protein (RnD 
Biosystems), and Doxoves®-Liposomal Doxorubicin HCl (FormuMax) and hyper branched polymer 
(HBP) based mPEG immobilized on ELISA plates. Individual wells of a 96-well maxisorp plate 
(Nunc) were coated with 100 μL of 10 μg/mL of HBP or Doxoves, or 10 μg/mL of target recombinant 
receptor (rHuPSMA) in 1 X PBS (pH 7.4) for 16–20 h at 4 °C. Following coating, the solution was 
decanted and 200 μL of 2% skim milk in PBST (PBS + 0.05% Tween 20) was added to each well for 
60 min to block nonspecific binding. The blocker was decanted and 100 μL of purified J591-mPEG 
BsAb was added into each well. The negative control anti-EGFR-mPEG BsAb [60] was used for 
rHuPSMA, and control PBS was used as a negative for the polymers. The experiment was tested in 
triplicate wells for statistical purposes. The BsAbs and PBS was incubated for 2 h and then decanted, 
followed by washing step using manually washed in PBST for five times. Then, 100 μL of HRP 
labeled anti-c-myc antibody (Miltenyi Biotech) diluted 1/5000 in blocker was added to each well and 
incubated for 30 min. The c-myc antibody was then decanted, followed by final washed for five times 
manually with PBST. The colorimetric reaction was performed by adding 100 μL of 3,3′,5,5′-
tetramethylbenzidine (TMB; Sigma) into each well, then incubated for 15 min or until adequate color 
development was identified. The TMB colorimetric reaction was neutralized using 100 μL of 2 M 
sulfuric acid and were immediately analyzed at an absorbance of 450 nm using the Spectramax plate 
reader. Average absorbance and standard deviation for each sample was determined and presented as 
histograms using excel software. 
This ELISA method was also used to confirm the specificity of J591-mPEG BsAb into mPEG 
molecules. Individual wells of a 96-well maxisorp plate (Nunc) were coated with 100 μL of 10 μg/mL 
of different size of linear mPEG molecules (MW of 2000, 5000, 10000, 20000, and 40000); hydroxyl 
PEG (OHPEG) linear as negative PEG molecules (MW of 2000, and 5000); HBP; and PBS.  All 
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polymers were derived from Sigma and Jomar Life Sciences. The following ELISA protocol was the 
same as mentioned above.   
3.2.7 Western Blot 
Binding specificity of the BsAb J591-mPEG was evaluated by western blot analysis using 
rHuPSMA and cell lysate PSMA expressing prostate cancer cells (PC3-PIP and LNCaP). PC3 
(PSMA negative) cell lysate was used as a negative control. Cell monolayers of the cells were 
removed from culture flasks with enzyme-free cell dissociation buffer (Gibco), centrifuged at 500 
rpm for 4 minutes and cell pellet was washed three times with ice-cold phosphate buffer saline (PBS). 
The cell pellet was solubilized in RIPA buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NonidetP-
40) (1 ml per 10 X 106 cells) and 1x protease inhibitor cocktail (Roche). Lysate were clarified by
centrifugation at 5000xg at 4 °C for 10 minutes and supernatants were recovered. BCA assay was
used to determine the concentration of protein using bovine serum albumin (BSA) as the standards.
Proteins (50-60 µg) were mixed with reducing buffer then separated by SDS-PAGE gel (Bolt 4-12%
Bis-Tris Plus gels, Invitrogen) and transferred onto PVDF membranes (Trans-blot Turbo Transfer
System, Bio-rad) and incubated with 5% milk blocking solution in 1 % tween in PBS (PBST) for 60
minutes, then with J591-mPEG BsAb (1/2500) in PBST milk at 4 °C for overnight. Membranes were
incubated with anti c-myc HRP secondary antibody (Invitrogen) (1/5000) in PBST milk for 60
minutes, then were washed three times with PBST before added developing solution (Novex ECL
Chemiluminescent, Invitrogen). The membrane was imaged using gel documentation system (Bio-
Rad) under chemiluminescent blots-high resolution method.
3.2.8 Binding analysis of BsAb on prostate cancer cell lines by flow cytometry 
The cell monolayer of prostate cancer cell lines were removed with enzyme-free cell 
dissociation buffer (Gibco), centrifuged at 500 rpm for 4 minutes and resuspended with fresh 10% 
FBS-PBS to give concentration of cells 2 x106 cells/mL. The BsAb at concentrations of 1× 10-6 M 
were added to 100 μL of cells (2 x 106 cell/mL) and incubated for 60 minutes at 4 °C. Following 
incubation, the cells were centrifuged gently at 2000 rpm for 2 minutes, the supernatant was pipetted 
off and the cells were washed three times with 200 μL of 10%FBS-PBS. After the final wash, the 
supernatant was removed from the cells and the pellet was resuspended in 50 μL of FITC labelled 
anti-c-myc secondary antibody (Miltenyi Biotec GmbH) diluted 1/11 in 10%FBS-PBS, then 
incubated in the dark for 60 minutes at 4 °C. Following incubation, the wash steps were repeated and 
then the cell pellet was resuspended in 100 μL of PBS for analysis by flow cytometry. Cells were 
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analyzed on the Accuri C6 Flow Cytometer using optical filter settings FL1 (533/30 nm) to detect 
FITC labelled secondary antibody. Data were evaluated using FCS Express 4 Flow based software. 
 
3.2.9 Bioconjugation of BsAbs-Cy5 labelled hyperbranched polymer 
 
 The bioconjugation was performed using a simple method, one-step mixing conjugation 
reaction. To evaluate the bioconjugation reaction, DLS analysis was performed to evaluate different 
particle size of bioconjugate compared to BsAb alone. 30 μL of BsAb at concentrations of 1 mg/mL 
were mixed with 4 μL of 2 mg/mL of Cy5 labelled methoxy-Poly-ethylene glycol hyperbranched 
polymer (m-PEG-HBP) (Kristofer Thurecht lab collection, AIBN). The confirmation of 
bioconjugation of BsAb into HBP and its binding ability into cell membrane expressing PSMA were 
also performed using the same in vitro targeting technique by flow cytometry experiment as protocol 
mentioned above without the additional of secondary antibody incubation step. Cy5 dye attached on 
the HBP was utilized to detect binding activity. Briefly, 100 μL of BsAb at concentrations of                     
1 × 10-6 M in 10% FBS-PBS were mixed with 100 μL of 1 × 10-6 M Cy5 labelled methoxy-Poly-
ethylene glycol hyperbranched polymer (m-PEG-HBP) in PBS by vortexing, then incubated in the 
dark for about 60 minutes. The negative control was used using the same concentration of Cy5 
labelled HBP which was mixed with PBS. The cells were then analyzed through FL4 (675/25 nm) on 
an Acuri C6 Flow Cytometer (BD Bioscience, San Jose, CA) to detect Cy5. Data were evaluated 
using FCS Express 4 Flow based software. 
 
3.2.10 Optimal ratio of BsAb to mPEG-HBP  
 
 To determine the optimal molar ratio of the BsAb J591-mPEG to mPEG on the hyperbranched 
polymer (HBP), free unbound BsAb into mPEG-HBP on the bioconjugate were measured by flow 
cytometry analysis. Six different molar ratios of bioconjugate were prepared (0.1:1; 0.5:1; 1:1; 2:1; 
5:1; and 10:1) using fixed amount of mPEG-HBP. The same flow cytometry procedure for binding 
analysis of BsAb-Cy5 labelled HBP conjugate were performed as mentioned above using PSMA 
positive prostate cancer cells, PC3-PIP. The cells were then analyzed through Cy5 channel. Data were 
evaluated using FCS Express 4 Flow based software. 
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3.2.11 Internalization and co-localization of BsAb-HBP bioconjugate into PSMA positive 
prostate cancer cells by confocal microscopy 
Cells were seeded on the coverslips until 80% confluence following which BsAb conjugated 
Cy5 labelled HBP (previously incubated at room temperature for 1h at ratio 1:1 in molarity) were 
added in fresh medium and incubated at 37 °C, 7.5% CO2 for 4 h. Following incubation, cells were 
washed with 1x PBS for three times then fixed with 4% paraformaldehyde (PFA) solution 0.5 mL for 
20 minutes at room temperature. The PFA were removed and the cells were washed with 1x PBS for 
three times. Finally, the cover slips were mounted on slides containing Vectashield ® with DAPI 
(Cole-Parmer). Slides were observed and imaged under a confocal microscope (Leica TCS SP8) at 
Australian National Fabrication Facility's Queensland Node (ANFF-Q).  
For co-localization study, the cell were settled down on the glass bottom dish (dish/glass: 
35/12mm) (WillCo Wells B.V) until 80% confluence. The bioconjugate (previously conjugated at 
ratio 1:1) were added in the fresh medium and incubated 37 °C, 7.5% CO2. After 24h, the cells were 
incubated with 5 µM LysoTracker Green DND-26 (Invitrogen) for 1 h in order to visualize lysosome. 
The medium were removed and the cells were washed with 1X PBS for three times, then fixed with 
4% PFA at room temperature for 10-20 minutes. Cells were gently washed with 1x PBS, and 1:2000 
Hoechst 33342 (Invitrogen) were added, and incubated for 10 min in room temperature. The staining 
solution was aspirated then the cells were washed with 1X PBS three times. The dish were observed 
and imaged under the Leica TCS SP8 confocal microscopy at ANFF-Q.   
3.2.12 In vitro cell uptake study of BsAb-conjugated Doxorubicin loaded HBP into PSMA 
positive prostate cancer cells by confocal microscopy 
Cells were seeded on the glass bottom dish (dish/glass: 35/12mm) (WillCo Wells B.V) until 
80% confluence. The cell media were discarded and replaced with fresh media containing either  4 
µg of free Doxorubicin (Dox) or BsAb-conjugated Dox loaded HBP (previously were mixed and 
incubated at room temperature for 1h at ratio 1:1 in molarity, containing 4 µg of Dox), then incubated 
at 37 °C, 7.5% CO2 for 24 h. The medium were removed and the cells were washed with 1xPBS for 
three times, then fixed with 4% PFA at room temperature for 10-20 minutes. The dish were observed 
and imaged using Dox channel under the Leica TCS SP8 confocal microscopy at ANFF-Q.   
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3.2.13 In vitro cytotoxicity study of BsAb-conjugated Doxorubicin loaded HBP  
 
 The PSMA positive prostate cancer cells, PC3-PIP were seeded in 96 well plate at a density 
3 x 103 cells per well in complete medium. The cells were incubated overnight at 37 °C, 7.5% CO2. 
The cells medium were replaced by 100 µL of fresh medium containing either free BsAb, HBP-DOX, 
BsAb-HBP-DOX, or free DOX at three different concentrations, each triplicate (the BsAb/HBP ratio 
on the bioconjugate were 2:1; the concentration of HBP-DOX and BsAb were following the DOX 
concentration). The cells only were also grown as control wells. The cells were then incubated for 48 
h, based on the optimum DOX released from the hyperbranched polymer, as described in previous 
research [179]. The cell viability assay were examined using CellTiter 96 Aqueous One solution 
Reagents, containing a novel tetrazolium 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS)] (Promega). Briefly, the cells were washed with 
200 µL of fresh medium before the addition of 100 µL complete medium containing 20% of MTS 
reagents (v/v). Plate were incubated at 37 °C, 7.5% CO2 for 1 h, and colorimetric reaction of each 
well were measured at the absorbance of 490 nm using Spectramax plate reader. The values of treated 
wells were normalized to control wells. Cell viabilities were statistically significance calculated using 
unpaired t-test with the significance P< 0.05.  
 
3.3 Results 
 
3.3.1 Protein production, purification and characterization 
 
 The J591-mPEG BsAb was created by fusing two scFvs with specificities for PSMA and 
mPEG, utilizing a glycine-serine (GS4) linker (Figure 3.1 A). A secretion signal peptide was 
incorporated at the N terminus of the gene construct to enable secretion of the BsAb from CHO cells 
during culture; also 6X His and c-myc tags were incorporated at the N- and C-termini respectively, 
for purification and detection purposes. The BsAb were successfully expressed into supernatant, 
detected by Western blot analysis using anti c-myc HRP secondary antibody (Figure 3.1 B). The 
expressed BsAb was purified from supernatant by a HisTrap column. The His eluate fraction was 
then desalted into HiPrep column to remove the imidazole for biological assay purposes. SDS-PAGE 
analysis showed the expected MW of ~ 56 kDa (Figure 3.1 C). Identification of protein was examined 
using peptide mass finger printing. Results showed that 98 % of J591-mPEG BsAb sequence are 
matched with 95% confidence interval (p<0.05) (Figure 3.1 D). 
 The native structure of the purified J591-mPEG BsAb was then evaluated using several 
analytical methods, including size exclusion chromatography (SEC), Dynamic Light Scattering 
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(DLS) and mass spectrometry (MS). SEC was used to estimate the molecular weight of the native 
protein, and to check the quality and size of protein, evaluating aggregation and/or degradation. The 
BsAb was analyzed by SEC on a Superdex 200 column run in PBS containing 20% ethanol.  The 
ethanol was incorporated to reduce non-specific interactions of the BsAb with the resin that were 
observed from preliminary studies. SEC results indicated no large aggregate peaks and two main 
peaks, a main peak at 14.4ml and a shoulder peak at 15.7ml retention volumes (Figure 3.1 E).  A 
comparison of the BsAb SEC profile with gel-filtration standard (Bio-rad) (Appendix A, Figure A.2) 
indicates a predicted molecular mass of BsAb in SEC is >158 kDa, which is much larger than 
expected molecular mass based on the amino acid sequence (~56 kDa) (Appendix A, Figure A.3). 
This larger MW than the one expected might be due to either protein dimerization or the partially 
intrinsic disorder character of J591-mPEG BsAb as predicted using algorithms (PONDR®) (Appendix 
A, Figure A.4). Another hydrodynamic technique was performed using DLS, an advanced method to 
measure particle size of molecule as well as to check the mono/polydispersity of macromolecule 
samples. DLS data displayed intensity of particle size distribution as shown in Figure 3.1 F. Results 
indicated polydispersity of sample with a prominent peak intensity of particle at diameter=7.4 nm. 
Polydispersity molecules might be explained by partially intrinsic disorder character of the BsAb [181, 
182].  
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Figure 3.1: Detection, identification and characterization of J591-mPEG BsAb expression in CHO cells. A) BsAb 
gene design and format tethering two scFvs, an anti PSMA (green) and an anti-PEG (red) joined with flexible G4S linker 
[61]. Secretion peptide (SP) is for BsAb secretion from CHO cells into medium. 6xHis and c-myc are for protein 
purification and detection. B) Western blot analysis of culture supernatant using anti c-myc antibody confirmed the 
expression of J591-mPEG BsAb with expected MW of ~56 kDa. C) Purified J591-mPEG BsAb showed the purity of 
protein. 1: protein marker; 2: BsAb. D) Peptide mass fingerprinting analysis showing peptides group and a sequence 
coverage map, with 97.9 % of J591-mPEG BsAb sequence was matched (p<0.05). Green indicates the peptide has been 
identified with at least 95% confidence, yellow indicates at least 50% confidence, and grey indicates no spectral evidence. 
E) Size exclusion chromatography profile run on Superdex 200 in 1x PBS containing 20% ethanol showed a main peak
at 14.4 mL, and a shoulder peak at 15.7 mL retention volume. F) Particle size distribution of purified BsAb using DLS
analysis showing heterogeneity molecules. Particle size distribution represents light intensity versus estimated particle
diameter with the main particle has 7.4 nm in diameter.
3.3.2 Immuno-assay using ELISA and Western blot 
To evaluate the affinity of the anti-J591-mPEG BsAb for respective antigens, an ELISA was 
employed utilising immobilized antigens, including PSMA and mPEG-containing polymers, 
allowing the BsAb to bind with specific antigens. The results demonstrated that the BsAb binds 
specifically to PSMA target, and also binds with mPEG-containing polymers in liposomal 
doxorubicin and HBP based methoxyl PEG. No signal was detected when the BsAb negative control, 
an anti-EGFR/mPEG BsAb, was added into immobilized rHuPSMA wells. Similarly, the control PBS 
did not show any binding to polymers (Figure 3.2 A). The binding of the BsAb was also screened 
against different size linear mPEG molecules and OHPEG molecules. It was evident that the BsAb 
bound specifically to linear mPEG with optimal binding to linear chains with Mw of 2000, 5000 and 
to a lesser degree 10,000 compared to no binding to OHPEG linear chains of 2000 and 5000. There 
was limited binding to 20K or 40K linear mPEG (Figure 3.2 B). In agreement with ELISA data, 
Western blot analysis of J591-mPEG BsAb showed the detection of  ~100 kDa band in rHuPSMA as 
well as in the PSMA-expressing prostate cancer cell, LNCaP and PC3-PIP cell extracts; PC3 cell 
extract (negative for PSMA) showed no protein band in Western blot (Figure 3.2 C).  
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3.3.3 Targeting efficiency of anti-PSMA J591-mPEG BsAb using flow cytometry analysis 
To evaluate the binding of J591-mPEG BsAb to membrane-expressed PSMA, we examined 
the BsAb using two prostate cancer cell lines expressing PSMA receptor, PC3-PIP and LNCaP cells, 
and PC3 prostate cancer cell (PSMA negative) as a negative control. Cells were incubated with 
purified BsAb followed by incubation with FITC-conjugated anti c-myc antibody, then analyzed by 
flow cytometry. The results showed that J591-mPEG BsAb only binds to PSMA positive, PC3-PIP 
and LNCaP cells, but not to PSMA negative, PC3 cells (Figure 3.2 D), indicating that J591-mPEG 
BsAb binds native PSMA receptor in prostate cancer cell lines. 
A  
B 
C   D 
 
Figure 3.2: Immuno assays and binding affinity of J591-mPEG BsAb into PSMA expressing prostate cancer cells. 
A) ELISA binding data for J591-mPEG BsAb (red) demonstrated specificity for recombinant human PSMA and polymers 
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containing methoxyl PEG in Doxoves®-Liposomal Doxorubicin HCl and mPEG Hyperbranced Polymer (HBP). Negative 
controls were used using anti-EGFR-mPEG BsAb (orange) and phosphate buffer saline (PBS) (blue), showing no binding 
into the receptor and polymer targets. B) The BsAb has a specific binding into methoxyl PEG, including mPEG HBP and 
linear mPEG with MW of 2K, 5K and 10K compared to Hydroxyl PEG linear chains of 2K and 5K; but limited binding 
to 20K or 40K linear mPEG. C) Western blot analysis of BsAb using rHu PSMA and the cell lysate of PSMA positive 
human prostate cancer cells, LnCAP and PC3-PIP, as well as PSMA negative human prostate cancer cell lysate, PC3 as 
a negative control. D) BsAb targeting prostate cancer using flow cytometry demonstrated specificity binding into PSMA 
positive, PC3-PIP and LNCaP cells, and no bind in PSMA negative, PC3 cells. Light blue: cells with PBS only (control); 
green: cells with J59-mPEG BsAb. 
3.3.4 In vitro analysis of BsAb-Cy5 labelled HBP targeting capability 
A previous study has shown that BsAb-Cy5 labelled HBP complexes can be formed in a 
simple and rapid reaction using one-step mixing of BsAb that exhibits dual specificity for mPEG and 
the target receptor [60]. In this study, the bioconjugation protocol is shown in Figure 3.3 A. BsAb was 
mixed with increased amounts of HBP, incubated briefly and analyzed by DLS. The amounts of HBP 
added to the bioconjugation reaction were too low for accurate size determination by DLS of HBP in 
the reaction. HBP alone were 5nm diameter (size confirmed by Thurecht group) was provided for 
experiments. The confirmation of bioconjugate was performed using DLS analysis. Results showed 
that the diameter particle size distribution of bioconjugate was 13 nm and larger compared to BsAb 
alone, which was 7.4 nm (Figure 3.3 B). Imaging of cells by flow cytometry or confocal microscopy 
requires a detectable fluorescent probe. We utilized a far-red-fluorescent dye, Cy5, attached to the 
polymers. Flow cytometry analysis of BsAb-Cy5 labelled HBP conjugate through the Cy5 filter 
channel showed enhanced uptake of the conjugate into PSMA expressing cancer cells in comparison 
to HBP alone (Figure 3.3 C). Confocal microscopy images confirmed that significant uptake and 
internalization of the conjugates can be observed in PSMA positive, PC3-PIP cells, with fluorescence 
detected through the Cy5 channel. In PSMA negative, PC3 cells, no fluorescence signal in Cy5 
channel was detected (Figure 3.3 D). In vitro co-localization studies were performed utilizing 
lysosome tracker, and showed that the conjugate was co-localized in the lysosome (Figure 3.4 E). 
These results demonstrated that J591-mPEG BsAb-Cy5 labelled HBP conjugates can effectively bind 
and internalize into cells expressing PSMA, making this conjugate an ideal candidate for further 
imaging development. 
31 
A 
B  
BsAb 
BsAb+HBP 
32 
 
C 
 
 
D 
 
E 
 
 
Figure 3.3: BsAb-Cy5 labelled HBP and its characterizations. A) Schematic representation of one step mixing 
antibody-NP conjugation of BsAb anti-PSMA-anti PEG and PEGylated hyperbranched polymer [7]. B) Particle size 
distribution of purified BsAb compared to BsAb-HBP conjugate using DLS analysis showing the increased diameter 
particle size of bioconjugate C) Flow cytometry of J591-mPEG BsAb-Cy5 labelled-HBP showing the bioconjugate has a 
binding activity into PSMA positive prostate cancer cell, PC3-PIP. Light blue: cells with PBS (control); orange: cells 
with HBP only; red: cells with BsAb-HBP conjugate. D) Confocal images showing uptake of Cy5-labelled HBP (red) 
following 1 h incubation of J591-mPEG BsAb-Cy5 labelled-HBP with PSMA positive LNCaP PC3-PIP cells and no cell 
uptake in PSMA negative PC3 cells. The cell nuclei were stained with DAPI. E) Immunofluorescent staining showing 
the co-localization of BsAb-HBP conjugate in cellular organelle (lysosome) in PSMA positive PC3-PIP cells (shown in 
white arrow in the merged image). 
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3.3.5 Optimal ratio of J591-mPEG BsAb to HBP using flow cytometry assay  
 
 To determine the optimal BsAb:HBP ratio in the one step mixing and formulation, 
formulations were prepared by mixing and vortexing the BsAb and HBP at six different molar ratios 
(0.1:1; 0.5:1; 1:1; 2:1; 5:1; and 10:1, with a fixed amount of mPEG-HBP) for 1 h at room temperature, 
before formulations were added to the PSMA positive PC3-PIP cells. As shown in Figure 3.4, the 
optimal BsAb:HBP molar ratio was around 5:1. The fluorescence intensity significantly increased 
with an increasing BsAb:HBP molar ratio (i.e. 0.1:1 to 5:1); however, the intensity was not 
significantly different between ratios of 5:1 and 10:1. 
 
3.3.6 In vitro cellular uptake and cytotoxicity studies of BsAb-conjugated Dox loaded HBP      
 
 To determine cell uptake and accumulation, as well as the ability of BsAb-Doxil conjugates 
to deliver Dox into cells, PC3-PIP cells were treated with BsAb-Dox loaded HBP and incubated for 
4h and 24 h. The free Dox was used as comparison to BsAb-Dox loaded HBP. These two formulas 
indeed demonstrated different cell uptake and accumulation behaviors. The free Dox was 
accumulated into the nucleus in 4 and 24 h. In contrast, the BsAb-Dox loaded HBP bioconjugate was 
retained in the outer nucleus membrane at 4h and at 24 h, the Dox was not released from the 
hyperbranched polymer. This suggest the in vitro stability of cellular uptake of Dox in NP 
formulation, without any undergoing degradation in the media (Figure 3.5 A).  
 The ability of BsAb-HBP conjugate to release the Dox into the cells was further characterized 
by a cell viability assay using the MTS assay. Cells were treated with the following formulations: 
free BsAb, HBP-Dox, BsAb-HBP-Dox and free Dox with varying concentrations of Dox, and 
incubated for 48 h. As shown in Figure 3.5 B, the HBP-Dox, BsAb-HBP-Dox and free Dox at 1μg/ml 
Dox concentration resulted in cell viabilities of 80%, 60%, and 30% respectively, whereas for the 
BsAb alone 90% cell viability was maintained. The results suggest that BsAb-conjugated HBP-Dox 
showed 20% enhancement in cytotoxicity compared to that of HBP-Dox. Similar trends were 
observed at 0.5μg/ml and 0.1μg/ml concentration of Dox when comparing HBP-Dox vs the BsAb 
targeted HBP-Dox.  BsAb targeted HBP-Dox had lower cell viabilities compared to HBP-Dox but 
cell killing effect was not as potent as 1μg/ml. 
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Figure 3.4: The optimal ratio of BsAb:HBP. Six different BsAb:HBP molar ratios (0.1:1; 0.5:1; 1:1; 2:1; 5:1; and 10:1, 
with fixed amount of mPEG-HBP) was assessed by flow cytometry analysis using PSMA positive PC3-PIP cells. 
Histogram (top) displayed as logarithmic scale (grey: cells with PBS (control), blue: cells with HBP alone, red: cells with 
BsAb-Cy5 labelled HBP conjugate). Bar charts (bottom) displayed linear scale, measuring median fluorescent intensity.   
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Figure 3.5: In vitro cellular uptake and cytotoxicity of BsAb conjugated Dox loaded HBP. A) Confocal fluorescence 
images PSMA expressing, PC3-PIP cells showing difference in uptake pattern in the cells treated with free Dox and Dox 
loaded BsAb-HBP conjugate. Images were taken after 4 and 24 h incubation time. B) The cytotoxicity of the BsAb, HBP-
DOX, BsAb-HBP-Dox and free Dox at concentration of Dox 0.1, 0.5 and 1 µg/ml on PSMA expressing, PC3-PIP cells 
at 48 has quantified by an MTS assay. The bar charts represent mean and ± standard deviation, n=3. *) statistical 
significance calculated using unpaired t-tests (Significance P<0.05). 
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3.4 Discussion 
 
 Active targeting of drug-loaded NPs to tumor cells offers the potential advantage of enhancing 
tumor cell uptake of cytotoxic drugs at the tumor site, compared to passive targeting. Although both 
active and passive targeting take advantage of the EPR effect, actively targeted drug delivery allows 
further potential for effective cytotoxic drug delivery to tumor cells via specific tumor receptors and 
can result in enhanced tumor regression compared to that of passive targeting. Furthermore, it shows 
significant advantages over free drug therapy, with overall lower drug dosage and less adverse 
reactions [183]. Lower drug concentration and dosing reduces the horrible side-effects experienced by 
patients receiving chemotherapy and also lowers financial burden. There are a range of conjugation 
methods for attachment of antibodies, proteins to nanomaterials for application in diagnostics, drug 
targeting and in vivo imaging.  Many of these traditional chemical conjugation methods are 
inefficient, require rigorous optimization. We engineered a novel bispecific format to facilitate 
antibody-NP conjugate as a versatile platform for precision nanomedicine. 
 In this study, we developed a BsAb that binds the PSMA receptor in prostate cancer cells and 
also binds a m-PEG-HBP. When the BsAb is mixed with drug-loaded HBP NPs at an optimized ratio, 
the BsAb-HBP bio-nanomaterial can be utilized as an actively targeted drug delivery system for the 
potential treatment of prostate cancer. This BsAb design allows conjugation between antibody and 
nanomaterials via non-covalent binding resulting in a highly stable and homogenous product.  
Several techniques have been used to generate BsAbs including cell fusion and hybridoma 
technology (e.g Catumaxomab) or recombinant DNA technology, combining two antibodies, or 
antibody fragments (e.g. Blinatumomab) [184]. In this research, we used two scFv antibody fragments, 
an anti-PSMA scFv J591 and an anti-mPEG scFv, fused with a glycine 4-serine flexible linker, to 
produce a BsAb in tandem scFv format. The flexible linker allows the two scFvs to retain binding 
activity for their respective antigens when they are assembled as a BsAb [185].  It has been reported 
that this format has the optimal design in terms of expression yield and with respect to binding into 
nanocells NPs, for drug delivery of drug-loaded NPs to tumor cells site [61]. Furthermore, this tandem 
scFv format is utilized, for example, in the bispecific T cell engager (BiTE®) technology, which has 
been used to produce Blinatumomab, a T-cell engager approved for treatment of Non-Hodgkins 
Lymphoma, and other BsAbs configured in the BiTE format which are currently in clinical trial [186, 
187].  
 It has been reported that scFv fragment offer several advantages compared to full-length IgG. 
An scFv fragment contains the smallest functional antigen-binding domain of antibodies, without the 
Fc region. Although the Fc domains are responsible for the function in antibodies (e.g. recruits 
antibodies effector functions and provides longer half-lives), there are situations where Fc- mediated 
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effects are undesirable. For instance, inappropriate activation of Fc receptor expressing cells may 
induce toxicity via cytokine release [188]. Therefore, the scFv format may display less immunogenicity 
than that of full length IgG antibody molecules, due to lack of the Fc domain, resulting in a lower 
immune response and avoiding the fast Fc clearance mechanism, while retaining almost affinity and 
specificity found in whole IgG  [189].   In term of antibody-NPs conjugate, scFvs are able to couple in 
a more oriented manner to the surface of NPs [190, 191]. In addition, scFvs promote better tissue 
penetration compared to whole mAbs. However, due to their smaller size compared to full length IgG 
molecules, BsAbs such as Blinatumomab, display rapid renal clearance, resulting in a short half-life 
[192, 193]. Therefore, in this study, the tandem scFv design for BsAb was chosen, whereby one arm of 
the BsAb binds to methoxyl PEG containing polymer, and the other arm binds the tumor target 
PSMA.  PEGylated NPs is common strategy to improve systemic circulation time. Due to the small 
size (around 55kDa), fast renal clearance of any BsAb that detaches from the NP would be expected.  
In terms of immunogenicity, the BsAb may display inherent immunogenicity, but would need to be 
tested in clinical trial. Conjugating of hyperbranched PEG polymer with the BsAb will impart multi 
valency and avidity of NPs, providing multiple binding sites into cancer receptor target [60]. Although 
the PEGylated NP possesses stealth properties, the non-covalent attachment of the BsAb to the 
exterior the PEGylated NP, forming a protein corona, may have an effect on these properties [194]. 
 The hydrodynamic analytical methods by SEC and DLS were utilized to investigate the mass 
and size distribution profile of the BsAb respectively. The results indicated the BsAb had an 
approximate molecular mass of 150 kDa by SEC, which is 2-3 times that predicted MW.  This 
suggests that the migration of the BsAb in the SEC matrix may be influenced by the protein structure 
or folding where this BsAb exists in different structural forms. As predicted by PONDR® protein 
disorder predictor, this BsAb with tandem scFv format of anti-PSMA/anti-mPEG scFvs might have 
partial intrinsically disordered protein (IDP) (Figure A.3) [182]. DLS is an in-solution method for 
determination of protein and particle sizes and unlike SEC is not influenced by the presence of a 
matrix.  The DLS data indicates a 7-8nm diameter structure which correlates with approximately 
50kDa protein.  The DLS profile displayed a polydisperse particle distribution, which might be due 
to the IDP or attributed to the presence of multimer and monomer species, which can also be linked 
to instability of BsAbs in storage buffer [61].  
 The binding specificity of the BsAb was evaluated using several methods, including ELISA, 
Western blot and flow cytometry. ELISA data confirmed that the J591-mPEG BsAb binds to PSMA 
antigen, rHu-PSMA, as well as mPEG containing polymers. In Western blot and flow cytometry 
analyses, the data demonstrated the BsAb binding specificity to PSMA antigen expressed on LnCAP 
and PC3-PIP cells (PSMA positive cell lines), with no cross reactivity with the PC3 cells (PSMA 
negative)  [195].    
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 It has been reported that J591 scFv binds the same PSMA epitope as the J591 complete IgG 
mAb, and so binding specificity is conserved with the J591 scFv format [196].  In this study we showed 
that our J591-mPEG BsAb binds to PSMA positive cell lines LNCaP and PC3-PIP cells, 
demonstrating that specificity for PSMA was conserved in the conversion of the J591 scFv to a 
tandem scFv BsAb format. Monovalent scFvs generally have lower overall affinity for their antigen 
compared to the affinity of bivalent IgG antibody molecules due to the avidity effect [197]. In the case 
of the tandem scFvs in this BsAb format, the BsAb forms a corona around the PEGylated HBP.  The 
anti-mPEG arm of the BsAb binds strongly to the HBP due to the abundance (multiplicity) of m-PEG 
epitopes on the HBP. The exterior of the NP is covered with the anti-tumor target arm of the BsAb, 
and so imparts avidity in binding to the tumor receptor. HBP offers targeting efficiency compared to 
other nanomaterials due to its smaller size owing  a greater potential in tumor penetration [198]. In 
addition, HBP provides multiple “arms” which allows for functionalizing with imaging and 
therapeutic agents. Importantly, the conjugation of BsAb with PEGylated HBP obtains a stable 
antibody-nanomaterial conjugate and improve the accumulation in tumor cells [60].  
 The bioconjugation of J591-mPEG BsAb and Cy5 labelled-HBP was carried out in a simple 
one step procedure, mixing the BsAb and HBP at an optimal molar ratio at room temperature to 
obtaining stable conjugation and homogeneous product [60]. The conjugation of the BsAb with HBP 
was confirmed by flow cytometry analysis, which also showed that the BsAb-HBP bionanomaterial 
binds to PSMA positive prostate cancer cells, LNCaP and PC3-PIP cells. Furthermore, the molar ratio 
of BsAb to HBP was optimized based on the fluorescence signal detected in flow cytometry analysis 
at six different BsAb:HBP molar ratios. As can be seen in Figure 3.6, the higher concentration of 
BsAb gave higher fluorescence intensity. However, the fluorescence intensity at ratio 5: 1 and ratio 
10:1 was not significantly different, suggesting that the optimal molar ratio of the BsAb to HBP 
should be around 5 to 10:1. 
We also investigated the internalization of BsAb-HBP conjugates into relevant cells using 
confocal microscopy. Previous studies showed that J591 mAb alone readily binds the plasma 
membrane in 5 minutes and internalized into the cell within 20 minutes [199]. It has been reported that 
J591 mAb-dendrimer conjugates are  internalized into PSMA positive LNCaP cells in 1 h [200]. In this 
study, we confirmed that 1 h incubation of BsAb-HBP conjugates within PSMA positive LNCaP and 
PC3-PIP cells resulted complete internalization. In addition, the co-localization study using organelle 
cell tracker (lysosome tracker) confirmed that BsAb-HBP conjugate was co-localized in the 
lysosome, suggesting that the internalization of BsAb-HBP conjugate in prostate cancer cells via an 
endosome-lysosome pathway. Therefore, this design is promising as an ideal vehicle for imaging and 
therapeutic drugs delivery. 
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 In this study, we utilized two different PSMA positive prostate cancer cells, including LNCaP 
and PC3-PIP for cell uptake and internalization studies using flow cytometry and confocal 
fluorescence images. Results showed a marked difference in cell uptake behavior and internalization 
in these PSMA expressing prostate cancer cells. The uptake of conjugate by LNCaP cells is 
consistently lower than that by PC3-PIP cells in flow cytometry data. In addition, difference staining 
profile are clearly seen between PC3-PIP and LNCaP cells for internalization of BsAb-HBP conjugate 
through immune fluorescent staining. These phenomenon might be influenced by the over expression 
of PSMA in PC3-PIP cells, as PC3-PIP cells were created  by transfecting PSMA encoding cDNA tr 
into PSMA negative PC3 cells [201], while LNCaP cells naturally express PSMA [202].  
 Importantly, we have demonstrated that the BsAb-HBP conjugate design could be utilized as 
a generic drug delivery system for the potential treatment of tumors with antibody-targeted, drug-
loaded NPs.  The cytotoxic drug Dox, loaded into the BsAb-HBP conjugate, exhibited excellent 
stability in the medium, as shown in the confocal microscopy images. The Dox in the HBP is able to 
be released at low pH, such as in the endosome, through hydrolysis of the hydrazone bond after 
internalization into the cells [179]. Molecular Dox is known to accumulate in the nucleus with minimal 
localization in vesicles. From confocal microscopy images, the Dox loaded BsAb-HBP was located 
in the outer nucleus membrane after 4 h incubation, and less than half staining the nucleus at 24 h, 
showing that the Dox was released in controlled manner. However, after 48 h, the Dox was 
successfully released from the BsAb-HBP-Dox conjugate and able to induce toxicity. The Dox in 
unconjugated HBP-Dox was also released into the cells with a lower cytotoxic effect compared to 
that of the Dox in conjugated BsAb-HBP-Dox. This suggests that attaching a ligand to the polymer 
which can specifically target PSMA positive prostate cancer cells, enhances the drug accumulation 
and cytotoxicity effects. In this in vitro cytotoxicity studies, the Dox loaded BsAb-HBP has a lower 
killing effect on cells as opposed to free Dox. This expected behavior, as the Dox in conjugated BsAb-
HBP-Dox are released in controlled manner, while free Dox can bind into DNA and are able to 
accumulate within nucleus in a shorter time. However, the previous study showed that in in vivo 
tumor regression experiments, the Dox loaded ligand-conjugated HBP has more therapeutic effect 
than the free Dox does, with the volume of tumor decreased by 90% compared to 30% from original 
volume over the 28 day period, respectively. It is suggested that the HBP did not lead the Dox release 
during circulation, and therefore not imparting non-specific toxicity in animals. In contrast, the free 
Dox has a rapid clearance from blood stream following intravenous injection, decreasing efficiency 
in tumor accumulation and has a detrimental effect in the overall health of animals. Therefore, BsAb-
HBP has an ability as targeted drug delivery carrier to increase therapeutic index and can reduce the 
amount of drug needed [179]. 
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3.5 Conclusion 
 
 In summary, we have succeeded in generating BsAb using the tandem scFv format, targeting 
PSMA receptor on prostate cancer cells and mPEG containing HBP, for actively targeting NPs with 
antibodies. This BsAb format is non-covalently bound into mPEG containing HBP using one step 
mixing method, offering simple, rapid and efficient method to target mPEG NPs. This conjugation 
method overcomes instability of antibody conjugated to NPs resulted from chemical conjugation, 
leading to homogenous orientation of ligand which allows specific targeting of mPEG NPs to PSMA 
expressing prostate cancer cells.  
 Due to multiple branches, the HBP used in this study can be functionalized by various cargos, 
including attachment of imaging dye and conjugation with cytotoxic drug. Therefore, the BsAb-HBP 
design has a potential to be used as an actively targeted nanocarrier for cancer diagnosis and 
treatment. 
 The mixing of an anti-PSMA J591-mPEG BsAb with HBP resulted a targeted nanomaterial, 
which specifically binds into PSMA expressing cells and also improve the cellular uptake of this 
nanomaterials in the PSMA positive prostate cancer cells.  Furthermore, in vitro studies confirm that 
attaching BsAb into drug loaded HBP facilitates enhanced drug accumulation and cytotoxicity effect 
compared to that unconjugated HBP.    
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Chapter 4 Incorporation of an azide-bearing unnatural amino acid into PSMA targeted scFv 
for molecular diagnostic applications 
 
4.1 Introduction 
  
 Chemical modification strategies are extensively used to conjugate molecular diagnostic 
and/or therapeutic entities to antibodies or other proteins. There are myriad of coupling reactions 
currently available for creating protein bioconjugates. The classical methods for these bioconjugation 
techniques utilize modification of cysteine and lysine residues. Other approaches are targeting the N- 
and C-terminus of proteins, and the modification of native disulphide bonds via the bis-alkylation 
mechanism [203]. However, there have been numerous reports in the literature of the limitations of 
bioconjugation techniques, that can result in heterogeneous mixtures of protein conjugates.  
 There have been recent reports of the incorporation of unnatural amino acids (UAA) into 
proteins, which can facilitate the conjugation chemistry of proteins for bioconjugation purposes [204]. 
UAA incorporation into proteins within living cells was first reported by the lab of Peter Schultz [205], 
to address the issues and problems that can arise through covalent modification of natural amino acid 
side chains, such as the generation of non-desirable products. UAA incorporation into proteins 
addresses this problem, rendering the highly specific coupling reaction with rapid and efficient under 
psychological conditions which can preserve the protein structure [206]. In addition, the site-specific 
incorporation of UAA into proteins by uniquely engineered tRNA/aminoacyl tRNA synthetase 
(tRNA/aaRS) pairs has gained interest as a promising modification strategy due to the feasibility of 
UAA addition at any site within any protein, irrespective of its size and solubility [207]. Currently, 
more than 200 UAA have been incorporated into proteins, and expressed in several living cell systems 
including bacterial, yeast, and mammalian [208]. In general, incorporating UAA into protein is 
achieved by introducing a non-sense codon, i.e. an amber codon (TAG) into the gene of interest, 
followed by co-transformation of additional plasmids encoding amino acyl-tRNA synthetase (aaRS)/ 
the suppressor tRNACUA pair.  The certain UAA is added into cell culture media. The aaRS will 
catalyze the acylation of the suppressor tRNACUA with the UAA. When the mRNA containing the 
amber codon is being translated in the ribosome, the amber codon is recognized by the tRNACUA 
charged with the UAA resulting the addition of this unnatural amino acid into the growing 
polypeptide chain [209]. 
 The most popular methodology of incorporating UAA into protein to facilitate selective 
bioconjugation via a covalent chemical bond formation is utilizing click chemistry reaction, including 
copper catalyzed azide alkyne cycloaddition, copper-free strain-promoted azide alkyne cycloaddition, 
photoclick cycloaddition, and inverse electron-demand Diels-Alder cycloaddition  [210]. As an 
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example, this method has been utilized by Moatsou et al. to incorporate azide bearing protein with 
the alkyne containing poly [(oligo ethylene glycol) methyl ether methacrylate] (PEGMA) polymer. 
They incorporated para-azido-phenylalanine (pAzF) UAA into protein at different positions to find 
the optimal optimum position that facilitates bioconjugation, while conserving protein structure and 
functionality. The incorporation of UAA into protein creates versatile protein mutant that are 
amenable to chemical conjugation, and which can be functionalized for a wide range of applications 
such as drug delivery, cellular imaging and molecular sensing [211].   
 Herein, we describe the expression in Escherichia coli of anti-PSMA J591 antibody single 
chain variable fragments (scFvs), with incorporated pAzF to facilitate the generation of a stable 
conjugate of anti-PSMA- pAzF with imaging dye or polymer, for targeting prostate cancer. The pAzF 
was genetically encoded into scFv by an engineered tRNA/aaRS pair derived from M. jannaschii that 
could incorporate pAzF in response to the amber codon TAG situated upstream at the N-terminus of 
the scFv gene coding sequences. Subsequently, the antibody fragment scFv-imaging dye/polymer 
conjugates were generated by the formation of a strong triazole linkage following strain-promoted, 
copper-free click chemistry reaction between the azide functional group in the pAzF incorporated 
scFvs and cycloalkyne functional group in the dibenzocyclooctyl (DBCO) containing fluorescent 
dyes or polymer. In this study, the characterization and verification of pAzF incorporation into J591 
scFv were investigated, as well as the successful biorthogonal reactions with DBCO containing dye 
and DBCO containing polymer. 
 
4.2 Materials and methods 
 
4.2.1 Cell lines 
 
 Human prostate cancer cell lines, PC3 (ATCC CRL-1435) which is PSMA negative cell; and 
PC3-PIP (PC3 transfected with human PSMA) which is PSMA positive cells, were cultured in RPMI 
1640 (Gibco) containing 10 % fetal bovine serum (Gibco). All cell lines were incubated at 37 °C in 
5% CO2. 
 
4.2.2 Polymers 
 
 DBCO-polymer model, DBCO-PEG4-DBCO (Jena Bioscience) with MW around 0.9 kDa 
was used as proved of concept for click chemistry reaction between azide-modified J591 scFv and 
polymer containing DBCO group. Diethyleneglycol methacrylate (DEGMA)-co-Pentafluorophenyl 
methacrylate (MAPFP) polymer with Dibenzocyclooctyne (DBCO) raft (DDM polymer) containing 
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Cy5 dye around 17.7 kDa in MW (unpublished) was kindly provided by Kris Thurecht group, AIBN 
UQ 
 
 4.2.3 Cloning and protein expression anti-PSMA J591 scFv incorporated pAzF 
 
 The anti-human PSMA J591 scFv sequence as mentioned above was synthesized and codon 
optimized for E. coli expression system by Geneart. Amber codon (TAG) was incorporated at the N-
terminus by PCR followed by the strep tag coding sequence and a 6x His tag coding sequence was 
incorporated at the C-terminus for purification and detection purposes. The amplified gene was 
cloned into pET26b for periplasmic protein expression to produce soluble protein. Recombinant 
pET26b containing J591 scFv with amber codon was co-transformed into BL21 (DE3) competent 
cells with pEVOL-pAzF (Addgene, Schultz lab collection, kindly provided by Dr Angus Johnson) 
encoding a tRNA synthetase/tRNA pair for the in vivo incorporation of p-azido-l-phenylalanine 
(pAzF) in response to the amber codon (Figure 4.1). Colonies were grown on LB medium with 
kanamycin (30 µg/mL) and chloramphenicol (34 µg/mL). A single colony was grown in LB liquid 
until OD600 reached 0.5-0.8, followed by the addition of 1 mM of IPTG (Astral Scientific), 0.05% of 
L-arabinose (Sigma ) and 3mM of pAzF (Iris Biotech, GmbH), then incubated at 20 °C; 200 rpm for 
16-20 hours. The cultures were harvested by centrifugation at 4000xg for 10 minutes. The soluble 
protein was extracted from the periplasm by resuspending cells thoroughly in 5mL of ice-cold sucrose 
solution per 1 gram cell pellet containing 30 mM Tris-HCl pH 8.0, 20 % (w/v) sucrose and 1 mM 
EDTA. The sample was incubated on ice for 30 minutes then centrifuged at 13.000 x g, 4 °C for 20 
minutes. The sucrose fraction was kept and saved on ice. After that, the cell pellet was dissolved in 5 
mL of ice-cold 5 mM MgSO4 per 1 gram cell pellet and 1x protease inhibitor cocktail (Roche), then 
lysozyme (Sigma) was added at final concentration 100 µg/mL.  The sample was incubated on ice for 
10 minutes then centrifuged at 13.000 x g, 4 °C for 20 minutes. The supernatant was kept on ice, then 
combined with sucrose fraction followed by dialysis against 1X D-PBS overnight at 4 °C, then 
purified by Strep-tag affinity chromatography. 
 
 
 
 
 
 
 
 
44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Design, cloning and expression of anti-PSMA J591 scFv incorporated pAzF in periplasmic space of E. 
coli system. A) Plasmid design, pelB; promoter for periplasmic expression; TAG: amber stop codon for unnatural amino 
acid attachment site; StrepTag: strep tag coding sequence for purification purposes; VH: variable heavy chain sequence 
of J591 antibody; linker: flexible linker (G4S)3; VL: variable light chain of J591 antibody; His6: Histidine 6 X tag for 
purification and detection purposes; Stop: stop codon. B) A schematic of unnatural amino acid (UAA) incorporation 
method in periplasmic E. coli expression system. Plasmid encoding J591 scFv were co-transformed with plasmid 
encoding the suppressor tRNA and amino acyl-tRNA synthetase (aaRS). The UUA pAzF were added into growth medium 
for subsequent tRNA acylation and its incorporation into J591 scFv. 
 
4.2.4 Protein purification 
 
 The protein was purified using StrepTrapTM HP 5 ml column (GE Healthcare), connected to 
AKTA purifier system, following provided manufacturer’s methods. Briefly, the column was 
equilibrated with binding buffer, containing 1 X PBS (20 mM sodium phosphate, 280 mM NaCl, 6 
mM potassium chloride) pH 7.4. Then, the filtered sample was applied into the column, and the flow 
through was collected.  The column was washed with binding buffer (washed fraction was collected), 
followed by elution step using buffer containing 2.5 mM desthiobiotin in binding buffer and the 
elution fractions were saved. The purified protein was also characterized using size exclusion 
chromatography (SEC) (Superdex 75 10/300, GE Healthcare), connected to AKTA purifier system 
using 1 X PBS as the binding and elution buffers.  
 
A  
B  
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4.2.5 Flow cytometry analysis of J591-scFv-pAzF 
 
 Cell monolayer of grown PC3 (PSMA negative) and PC3-PIP (PSMA positive) cells were 
removed with enzyme-free cell dissociation buffer (Gibco), centrifuged at 500 rpm for 4 minutes and 
resuspended with fresh 10% FBS-PBS to give concentration of cells 2 x106 cells/ml. The scFv at 
concentration of 1× 10-6 M were added to 100 μL of cells (2 x 106 cell/mL) and treated as protocol 
described previously. FITC labelled anti-His secondary antibody (Miltenyi Biotec GmbH) was used 
as the secondary antibody. Then cells were analyzed on the Accuri C6 Flow Cytometer using optical 
filter settings FL1 (533/30 nm) to detect FITC labelled secondary antibody. Data were evaluated 
using FCS Express 4 Flow based software. 
 
4.2.6 Click chemistry reaction of J591 scFv-pAzF toward Cy5 labelled DBCO 
 
 The incorporation of pAzF into J591 scFv was evaluated by copper-free click chemistry 
reaction using Cy5 labelled-DBCO (Sigma-Aldrich). 10µg of purified protein was mixed with 1µl of 
Cy5 labelled-DBCO, then incubated at 4 °C overnight. The reaction was evaluated by SDS-PAGE 
and detected through Cy5 channel protein imaging (ChemiDoc Imaging system, Bio-Rad).  
 
4.2.7 Binding and internalization studies of Cy5 labelled DBCO conjugated J591-scFv-pAzF 
into prostate cancer cells  
 
 Target binding efficiency of conjugate was performed using flow cytometry analysis. The 
conjugates were incubated in PC3 and PC3-PIP cells and treated as protocol described above without 
the additional of secondary antibody incubation step. The cells were then analyzed on CytoFlex Flow 
Cytometer Platform (Beckman Coulter) through APC channel (690/50) to detect Cy5. Data were 
evaluated using FCS Express 4 Flow based software. 
 For internalization study, the Cy5 labelled DBCO conjugated J591-scFv-pAzF were 
incubated in the grown cells (PC3 and PC3-PIP cells) with around 80% confluence at 37 °C, 7.5% 
CO2 for 4 h. Following incubation, cells were washed with 1x PBS for three times then fixed with 
4% paraformaldehyde (PFA) solution 0.5 mL for 20 minutes at room temperature. The PFA were 
removed and the cells were washed with 1x PBS for three times. Finally, the cover slips were mounted 
on slides containing Vectashield ® with DAPI (Cole-Parmer). Slides were observed and imaged 
under a confocal microscope (Leica TCS SP8) at Australian National Fabrication Facility’s 
Queensland Node (ANFF-Q).  
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4.2.8 Click chemistry reaction of DBCO-PEG linker as a polymer model into J591 scFv-pAzF 
 
 20 µl of 10 µM J591-pAzF was mixed with 2 µl of 10 mM DPD, then incubated at 37 °C, 
overnight with shaking at 300 rpm. The unconjugated DPD were removed through the 0.5 mL zeba 
spin desalting column with 7 kDa MWCO (Thermosfisher), following provided manufacturer’s 
protocol. The reaction were incubated again for another overnight in the same reaction conditions. 
The conjugated and unconjugated scFv’s were then analyzed using SDS PAGE.  
 
4.2.9 Verification of J591 scFv-pAzF-DPD conjugation by Mass Spectrometry 
 
 Protein (~1 µ g) was analyzed using an Orbitrap Elite (Thermo) mass spectrometer and 
Dionex Ultimate 3000 nano LC system (Thermo).  Sample was first desalted on a C4 PepMap300 
pre-column (300 um x 5 mm, 5um 300A) using buffer A (30 ul / min) for 5 min and separated on an 
C4 Acclaim PepMap 300 (75 um x 150 mm) at a flow rate of 300 nL / min.  A gradient of 10-70% 
buffer B over 10 min, followed by 70-98% buffer B over 0.5 min was used, where buffer A was 0.1% 
formic acid in water and buffer B was 80% acetonitrile / 0.1% formic acid.  Eluted protein was directly 
analyzed on an Orbitrap Elite (Thermo) mass spectrometer interfaced with a NanoFlex source.  MS 
was operated in positive ion mode using the ion trap analyzer.  Source parameters included an ion 
spray voltage of 2.4 kV, temperature at 275° C, SID = 30V, S-lens = 70V, summed microscans = 3, 
FT vacuum = 0.1.  MS analysis was performed across 800 – 2000 m/z.  Data was deconvoluted using 
Thermo Protein Deconvolution ™ software across mass 1100-1800 m/z with minimum of 6-10 
adjacent charges, target mass of 30 or 60 kDa as needed, and charge state range 10-100. Deconvoluted 
data is reported as average mass. 
 
4.2.10 Click chemistry reaction of DEGMA-co-MAPFP polymer with DBCO raft (DDM 
polymer) with J591 scFv azide 
 
 Before the conjugation reaction, the DDM polymer was dissolved in water and kept stirring 
at 4 °C. Then, J591 scFv were added to the DDM polymer solution and the mixture was allowed to 
react overnight at 4°C. For a typical preparation, 5mg of DDM polymer (0.72 µmol) and 1 mg of scFv 
(0.036 µmol) were used (scFv to polymer ratio of ~1:20). After conjugation, samples were kept at 
60°C for 10 minutes which will make the polymer insoluble. Upon centrifugation (1.4 rcf for 10 
minutes), polymer scFv conjugate forms pellet and free scFv remains in the supernatant. The pellet 
was freeze dried and redissolved for further characterizations. 
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The conjugation reaction were analyzed using SDS PAGE. The bioactivity of conjugate was also 
confirmed by flow cytometry assay using PSMA expressing prostate cancer cells PC3-PIP with the 
protocol mentioned previously. The polymer alone was used as a negative control.  
 
4.3 Results 
 
4.3.1 Modified scFv production and bioactivity assay 
 
 Incorporation of azide-containing unnatural amino acid, pAzF, into J591 scFv was carried out 
using a periplasmic E. coli expression system, by co-transforming the pEVOL-pAzf plasmid 
encoding the aminoacyl-tRNA synthetase/suppressor tRNA pair, and an appropriate plasmid 
containing TAG amber codon at the N-terminus, into competent cells BL21 (DE3). A positive clone 
was selected and expressed in LB medium with appropriate inducers and amount of pAzF. The cells 
were harvested, followed by periplasmic extraction using the combination of EDTA-lysozyme and 
cold osmotic shock. The overall yield of J591 scFv-pAzF in periplasmic E. coli was up to 5-6 mg/L. 
The J591 scFv pAzF extracts were purified using Strep-tagged protein purification resulting in a 
protein preparation of high purity (Figure 4.2 A). The purified scFv was characterized by size 
exclusion chromatography confirming that the purified scFv preparation was predominantly 
monomeric protein, with a small percentage of dimers and protein aggregates (Figure 4.2 B). To 
evaluate targeting efficiency into membrane-expressed PSMA, the binding specificity of J591-scFv 
was verified using flow cytometry, utilizing PSMA-expressing prostate cancer cells (PC3-PIP) and 
PSMA negative prostate cancer cells (PC3), as the negative control.  Flow cytometry results showed 
that scFv has binding specificity for PSMA receptor, as shown in Figure 4.2 C.   
 
4.3.2 Verification of azide-modified unnatural amino acid incorporation by click chemistry 
reaction toward DBCO containing imaging-dye 
 
 To confirm the site-specific incorporation of UAA pAzF into anti PSMA J591 scFv, the click 
chemistry reaction of dibenzocyclo-octyne (DBCO) derivative toward mutant scFv was examined. 
DBCO-labelled Cyanine 5 dye was mixed with scFv; wild-type J591 scFv was used as a negative 
control. Coomassie blue staining clearly showed the bands of both mutant and wild type scFvs. 
However, fluorescent imaging of mutant scFv revealed a clear band, while the wild type scFv did not 
show any fluorescent labelling (Figure 4.3). Therefore, the results confirmed that the azide containing 
UAA has been successful incorporated into J591 scFv.  
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4.3.3 In vitro internalization study of scFv-dye conjugate uptake into prostate cancer cells 
 
 The internalization of J591 scFv-pAzF - DBCO Cy5 conjugate evaluated by 
immunofluorescence read out flow cytometry analysis through Cy5 channel (Figure 4.4 A) indicated 
that the conjugates specifically bind to PSMA expressing prostate cancer cells. In addition, 
immunofluorescence staining imaged using confocal microscopy showed that the conjugate was fully 
internalized into PSMA positive PC3-PIP cells, while no binding and internalization into PSMA 
negative PC3 cells was evident (Figure 4.4 B).  
 
A               B 
                         
 
 
C 
    
     525/40- FITC                      525/40- FITC  
 
Figure 4.2: Purification and affinity binding assay of J591 scFv-pAzF. A) SDS PAGE of purified J591 scFv-pAzF 
showing ~28 kDa in MW. B) Size exclusion chromatography shows that the scFv expressed in periplasmic space contains 
mainly monomeric protein with low protein aggregates and protein dimers.  C) Flow cytometry analyses indicated that 
J591 scFv-pAzF can specifically bind into PSMA positive human prostate cancer cell line (PC3-PIP), but not into negative 
cell line (PC3). Histogram, grey: cells with PBS (control); red: cells with J591 scFv pAzF. 
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Figure 4.3: Evaluation of UAA pAzF attachment into a single-chain fragment variable (scFv) of J591 antibody and 
its binding analysis. A) Copper-free click chemistry reaction of Cy5 labelled DBCO with J591 scFv-pAzF. B) 
Comparison between J591 scFv wild type and J591 scFv-pAzF in coomassie blue and chemiluminescence Cy5 channel; 
M: protein marker; 1: J591 scFv wild type; 2: J591 scFv-pAzF.  
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Figure 4.4: In vitro binding specificity and internalization studies of azide-modified J591-scFv conjugated into 
Cy5-labelled DBCO. A) Flow cytometry assays showed that the scFv dye conjugates specifically binds into PSMA 
positive prostate cancer cells (PC3-PIP) and not into PSMA negative prostate cancer cells (PC3). B) Immunofluorescence 
analyses also showed the specificity of scFv dye conjugate in PSMA expressing prostate cancer cells (PC3-PIP). 
 
4.3.4 Conjugation of azide-modified J591 scFv into DBCO PEG linker 
 
To verify whether J591 scFv-pAzF can be used to attach other molecules, a DBCO PEG linker with MW 
around 1 kDa was chosen for copper-free click chemistry reaction, as a testbed for larger polymer. The linker 
has two DBCO molecules in the opposite arms which can be coupled into azide-bearing scFv (Figure 4.5). To 
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evaluate the conjugation, SDS PAGE analysis was performed. Results showed that more than one bands appear 
on the gel for conjugated sample as can be seen in Lane 3 in Figure 4.6 A. In addition, the less intense band of 
degraded protein of unconjugated scFv was also detected, as can be seen on the gel with lower MW at ~19 
kDa (Lane 2).  Further analysis was then performed using intact mass spectrometry to verify the MW of each 
band. In the unconjugated scFv, the intact mass was shown to be around 27-28 kDa. However, lower MW 
species for degraded protein was not detected (Figure 4.6 B). In the conjugated scFv, the intact mass results 
shown the same average mass with unconjugated scFv, i.e. around 27-28 kDa, and one higher species with 
average mass of 47 kDa (Figure 4.6 C). These results confirmed there were excess unconjugated scFvs in the 
mixture of product, and some scFvs were successfully conjugated with 1 kDa DBCO PEG linker in both sides. 
However, it is presumed that one side of DBCO reacted with 27 kDa scFv and another side of DBCO reacted 
with lower MW of degraded scFv which has around 19 kDa based on SDS PAGE gel result. 
Figure 4.5: Copper-free click chemistry reaction of J591 scFv-pAzF and DBCO-PEG linker under physiological 
condition.  
+  
DBCO-PEG4 -DBCO Azide-modified J591 scFv 
J591 scFv-DBCO-PEG4 –DBCO-J591 scFv 
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Figure 4.6: Verification of conjugation of DBCO-PEG4-DBCO with J591 scFv-pAzF. A) SDS PAGE show the 
unconjugated and conjugated scFvs. Lane 1: Marker; lane 2: unconjugated scFv; lane 3: conjugated scFv shows several 
bands containing excess scFv (unconjugated) and scFv-polymer conjugates. B) Deconvoluted masses for unconjugated 
scFv as reported by Protein Deconvolution software. C) Deconvoluted masses for conjugated of scFv-DPD as reported 
by Protein Deconvolution software, measuring two MW species including excess scFv (unconjugated), and a higher MW 
species of ~47 kDa. 
Unconjugated J591 scFV-pAzF (lane 2) 
Conjugated J591 scFv-pAzF (lane 3) 
Degraded protein 
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4.3.5 Conjugation of azide-modified J591 scFv into DEGMA-co-MAPFP polymer  
 
 For the conjugation of J591 scFv-pAzF with a higher MW polymer, an alkyne group formed 
as DBCO was incorporated in RAFT block co-polymer consists of DEGMA block and MAPFP 
prepared using RAFT agent at (~17.7 kDa). Cy5 fluorophore agent was incorporated within the 
polymer chain through the reaction with MAPFP for detection purposes. The conjugation of DBCO-
functional group polymer with azide-bearing proteins was carried using copper free-click chemistry 
reaction. To evaluate the conjugation, we performed SDS PAGE and imaged the conjugation trough 
Cy5 filter. It was proposed that covalent attachment of protein via azide UAA to DBCO-polymer may 
influence the migration of Cy5-polymer. Results confirmed that the protein was successfully 
conjugated into polymer as can be seen under Cy5 channel. There was no signal in unreacted scFv, 
while smeared bands were shown for polymer alone and the conjugate. The conjugation reactions 
were also imaged after coomassie blue staining. The conjugates appeared on the gel as a smeared 
band with higher MW, compared to a distinct unconjugated scFv band (Figure 4.7 B). Such smears 
are commonly seen in protein-polymer conjugates, as well as in polymers alone due to the variation 
in polymer MW [212, 213]. Following protein-polymer bioconjugation, we then carried out flow 
cytometry analysis to confirm the protein-polymer bioconjugation as well as to evaluate binding 
ability of bioconjugation into cells expressing PSMA receptor. Results showed that the J591 scFv-
pAzF - DBCO RAFT polymer conjugate binds into PSMA positive PC3-PIP cells. Flow cytometry 
histogram showing a shift in protein-polymer conjugates through Cy5 filter compared to control PBS 
and polymer alone (Figure 4.7 C). 
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660/20- Cy5 
Figure 4.7: Analysis of J591-scFv- DDM polymer conjugates. A) Structure of DEGMA-co- MAPFP with DBCO 
RAFT (DDM) polymer (right); J591 scFv incorporated pAzF in N-terminus (left). B) SDS PAGE of the protein upon 
conjugation with polymer detected with Cy5 channel (right) and coomassie blue (left): M, marker; lane 1, J591 scFv-
pAzf alone; lane 2, DBCO RAFT polymer alone; lane 3, J591-scFv- DBCO RAFT polymer conjugates. Red arrow shows 
the bioconjugates. C) Flow cytometry plots show Cy5 fluorescence in PSMA positive PC3-PIP cells incubated with J591-
scFv-pAzF DBCO RAFT polymer conjugate: grey, control PBS; red, polymer alone; blue, J591-scFv- pAzF DBCO 
RAFT polymer conjugate. 
4.4 Discussion 
The incorporation of UAA into proteins and subsequent production in various cellular 
expression systems, has proven to be a novel method for protein engineering. Through residue-
specific incorporation, the engineering of both physical and chemical properties of proteins is 
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Coomassie blue Cy5 Channel 
 PC3-PIP M     1  2  3
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possible, while incorporation at specific sites minimizes structural changes, thus conserving 
functionality. In this study, we used pAzF providing azide functionality, which was incorporated at 
the N-terminus of J591 anti-PSMA scFv. The incorporation of azide-bearing UAA facilitates 
biorthogonal click chemistry reactions via azide-alkyne cycloaddition. Since the TAG amber codon 
is a stop codon, the position of the TAG codon at the upstream of the gene encoding scFv ensures the 
generation of only homogeneous products, that is only anti-PSMA J591 scFv incorporated with pAzF. 
In addition, the incorporation of azide at N-terminal of scFv is favorable, as this position is solvent 
exposed and generally accessible for further chemical modifications [214].  
 For production a mutant J591 scFv with UAA incorporation, we expressed the protein in a 
periplasmic E. coli production system to obtain soluble protein at high yield, avoiding protein 
aggregation and suppressing the formation of dimers. In agreement with a previous study, soluble 
J591 scFv-pAzF expressed well in the periplasmic space of E. coli, with a low amount of dimer and 
the absence of aggregates. However, our results showed that the overall yield of soluble periplasmic 
J591 scFv-pAzF was about half of the yield of soluble periplasmic wild type scFv previously reported 
by Frigerio et al., 2013 [215]. This study showed that in general, expressing protein with UAA 
incorporation using amber codon has a limitation in term of protein yield [216]. The main reason for 
the low yield of UUA incorporated protein in comparison to the wild type is presumably due to 
inefficient translation caused by an incompatibility of orthogonal synthetase and its suppressor tRNA 
pairs with host cell organisms [208]. In addition, when standard periplasmic E. coli expression systems 
are utilized, our mutant scFv product is mostly expressed as inclusion body in the cytoplasmic space 
(data not shown). The tendency for protein accumulation as insoluble protein is probably due to the 
lack of processing signal peptidase, resulting the J591 scFv-pAzF failed to translocate into the 
periplasmic space of E. coli. However, this study suggests that expression of J591 scFv-pAzF in the 
periplasmic expression system is still superior compared to that in the cytoplasmic expression systems 
[217]. The disadvantages of expressing in the cytoplasmic space is the need for resolubilization from 
inclusion bodies and refolding of the protein which is an inefficient process, and can also produce 
protein aggregates and dimers. However, the most important reason for the unsuitability of 
cytoplasmic expression is the instability of the azide group in the presence of reducing agent, such as 
dithiothreitol (DTT), which is an essential agent in inclusion body solubilization and recombinant 
protein refolding. DTT, used for the reduction of disulphide bonds in this mutant scFv, can reduce 
the azide in pAzF to a corresponding amine group, resulting non-functional azide and prohibiting  
chemical conjugation reactions [218, 219]. Therefore, we found that the efficient production of azide-
bearing UAA incorporated into J591 scFv is in periplasmic E. coli expression system.   
 To evaluate the biological activity of the mutant scFv, a binding specificity assay using flow 
cytometry analysis was performed. The purified mutant scFv showed binding activity to PSMA-
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expressing prostate cancer cells PC3-PIP, and showed no binding to PSMA-negative, PC3 prostate 
cancer cells. This binding study proved that the incorporation of azide-bearing unnatural amino acids 
at the N-terminus preserves the specific binding activity of the J591 anti-PSMA scFv.  Following 
this, a biorthogonal reaction was performed to confirm the incorporation of azide UAA into J591 
scFv using copper-free cycloaddition by employing cycloalkyne from DBCO, which is highly 
reactive towards the azide group. This catalyst-free click reaction avoided the use of the cytotoxic 
Cu(I) catalyst, which has been widely used in alkyne-azide cycloaddition. The DBCO containing 
cyanine dye (Cy5) was used for the copper-free click chemistry reaction and mixed with either wild-
type J591 scFv or J591 scFv-pAzF. The detection under Cy5 channel confirmed that only mutant 
scFv containing azide group had been clicked with the DBCO group (Figure 4.3 B). Furthermore, in 
vitro binding studies were performed to evaluate the J591 scFv-pAzF conjugated Cy5 labelled DBCO 
using flow cytometry and confocal microscopy. Results showed that the scFv labelled with Cy5 dye, 
confirming the successful conjugation and has a specific binding and internalization into PSMA 
positive prostate cancer cells, PC3-PIP. 
 The accessibility of the azide group incorporated at the N-terminus of scFv for coupling 
reaction was further evaluated through copper-free cycloaddition click chemistry reaction with 
DBCO containing polymers. Firstly, the reaction was demonstrated by reacting J591 scFv-pAzF with 
~1 kDa PEG4 linker containing two DBCOs in the opposite arms. SDS-PAGE and intact mass 
analyses showed that the scFv was successfully conjugated to DBCO-PEG linker in the both sides. 
However, since degradation of protein was detected (Figure 4.6 A), the degraded scFv were 
conjugated into DBCO at one side of PEG linker. This might be because one side of DBCO in the 
linker is more sterically hindered compared to the other side, so that the less sterically hindered DBCO 
site was more amenable to react with degraded azide-scFv of lower MW. Secondly, the evaluation of 
azide accessibility for biorthogonal reaction was performed by reacting the Cy5 labelled DBCO 
containing DEGMA-co-MAPFP polymer (MW; ~17.7 kDa) with J591 scFv-pAzF. Results showed 
that the scFv was successfully conjugated to the DBCO polymer, confirmed by the SDS-PAGE 
analysis under Cy5 channel. Furthermore, flow cytometry analysis proved that the conjugate had 
binding specificity to PSMA-expressing prostate cancer cells. 
   
4.5 Conclusion 
 
 There are a myriad of covalent conjugation methods that have been widely researched to 
obtain a stable conjugate for successful targeting of mAb to NPs. For conjugation, a suitable 
functional group has to be incorporated into the mAb or the surface of NP. In this research, we have 
successfully in vivo incorporated an UAA in E. coli expression system to functionalize the antibody 
57 
 
fragment anti-PSMA J591 scFv with azide group at the N-terminus providing bioorthogonality and a 
higher degree of specificity. Additionally, we have improved the efficient production of this modified 
scFv by expressing the protein in periplasmic space to obtain highly monomeric protein yields.    
 In this study, we have successfully conjugated the azide-modified J591 scFv with DBCO 
containing imaging dye or polymers through copper-free cycloaddition click chemistry reaction, 
which proves a highly accessible of azide moiety in this mutant scFv for conjugation reaction. This 
covalent binding conjugation demonstrate a stable linkage, which exhibits the potential of various 
bioconjugations, such as for targeted imaging and therapeutic applications. In particular, we have 
demonstrated that the J591 scFv-pAzF- imaging dye/polymer conjugates are able to specifically bind 
into PSMA expressing prostate cancer cells. Further development of antibody-NPs conjugate via 
copper click chemistry reaction by controlling the density of ligand in polymeric micellar system will 
identify the interaction of this designed nanomaterial into target cells.   
 Finally, this technology has the potential to be applied for other targeted nanomedicines, such 
as through covalently coupling to nanomaterial which has theranostic capabilities, or directly 
conjugating with cytotoxicity drug/toxin as antibody drug conjugate.  
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Chapter 5 In vivo evaluation of biodistribution and tumor accumulation of antibody fragment-
polymer/imaging dye conjugates in PSMA-positive tumor xenograft 
 
5.1 Introduction 
 
 The creation of bionanomaterials through attaching a targeting ligand such as an antibody 
fragment to a nanomaterial, for the active targeting of nanomedicines, has shown some potential in 
animal studies, which are essential investigations prior to clinical testing. Nanomedicine formulations 
(i.e. drug-loaded nanomaterials), have shown clinical benefits through improvement of 
pharmacokinetic profiles and reduced toxicity, compared with systemic delivery of chemotherapeutic 
drugs [220, 221]. Furthermore, actively targeted nanomedicine has a major advantage in a selective 
delivery of NPs to the specific tumor targets, remaining in the site for an extended period of time, 
thereby increasing the local accumulation of the NPs specifically to tumor sites [3, 222-224].  Antibodies 
and antibody fragments are attractive ligands for the active targeting of nanomaterials, due to their 
binding specificity for tumor targets. Several antibodies or antibody fragments conjugated to  
radiolabels, have been approved by FDA for cancer imaging, such as  Capromab pendetite 
(ProstascintTM) for prostate cancer imaging, Arcitumomab (CEA-Scan™) for diagnostic imaging of 
colorectal cancer, and Nofetumomab merpentan (Verluma™) for small cell lung cancer imaging [225]. 
There are many studies that report the use of antibodies or antibody fragments for in vivo imaging for 
biodistribution studies and tumor accumulation in xenograft tumor models [226, 227]. Numerous 
research have  also described in vivo biodistribution studies of NPs relative to NP size, shape, charge 
and surface chemistry for different biomedical applications [27]. However, only few reports are found 
on in vivo biodistribution and tumor accumulation studies with antibody functionalized NPs.  
 NPs naturally accumulate into tumor sites through EPR effect, which makes them as an 
excellent tool for imaging and therapeutic applications [228].  One drawback of passive targeting of 
NPs via EPR is the lack of specificity to tumor sites. However there is potential to improve specificity,  
cellular uptake and tumor accumulation of NPs using an active targeting approach by the decoration 
of NPs with targeting ligands such as antibodies. It has been demonstrated that antibodies or antibody 
fragments conjugated to various NPs have more effect on tumor accumulation compared to 
unconjugated NP in xenograft mice models [229-231], confirming that the specific targeting of 
functionalized NPs is enhances accumulation and promote cellular uptake. This active targeting NPs 
has promising findings in some preclinical and early clinical studies. However, some studies reported 
the addition of targeting ligands may contribute to protein corona formation on NPs which can inhibit 
the biological functions of this bioconjugate and increased the elimination of NPs through  
mononuclear phagocyte system (MPS) [232]. This highlights the pros and cons of actively targeted 
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NPs in an in vivo and clinical setting and the importance for clever design and development of actively 
targeting NPs.  
In vivo kinetic biodistribution and tumor accumulation may differ between different types 
antibody formats, and antibody-NP conjugates, which influence the utilization in imaging and 
therapeutic applications. For diagnostic applications, targeting tumor deposition combined with rapid 
blood clearance are required, and minimal accumulation in healthy tissues to increase imaging 
contrast.  While, in therapeutic applications, longer circulation times are desirable while minimizing 
accumulation and toxicity in healthy tissues [226]. 
 Here we evaluated in vivo imaging properties, biodistribution, and tumor accumulation of two 
antibody targeted formats that have been developed, including J591-mPEG BsAb-conjugated 
imaging dye labelled PEGylated HBP and J591 scFv-pAzF-conjugated imaging dye labelled DBCO 
in xenograft mice models. We also demonstrated ex vivo images to support in vivo data and evaluated 
the xenograft tumor uptake as well as the distribution into functional organs, such as kidneys, lungs, 
spleen and hearth. 
 
5.2 Materials and methods 
 
5.2.1 Animals 
 
 For all animal models, eight-week-old Balb/c nude mice were acquired from the University 
of Queensland's Biological Resources and were allowed access to food and water ad libitum 
throughout the experiment. All the studies were approved by the Animal Ethics Committee of the 
University of Queensland, and Australian Code for the Care and Use of Animals for Scientific 
Purposes (see Appendix B). 
 
5.2.2 Antibody fragment- polymer/imaging dye conjugates 
 
 All the antibody fragments and the conjugation methods were prepared as mentioned in 
chapter 3 and 4, including J591-mPEG BsAb which was non-covalently conjugated to Cy5 labelled 
HBP, and J591 scFv-pAzF which was covalently conjugated with Cy7 labelled DBCO through a click 
chemistry reaction.  
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5.2.3 In vivo biodistribution, and tumor accumulation of BsAb-HBP bioconjugate in tumor 
bearing mice  
 
6 male Balb/c nu/nu mice (eight weeks old) were anaesthetized using 2% isofluorane and 
injected with 2x 106 PC3 cells in the right flank and 2x 106 PC3-PIP cells in the left flank to induce 
subcutaneous tumors. The tumors were grown for 20 days. The mice were split into 2 groups for 
experiments, Cy5 labelled HBP alone (non-targeted control) (n=3), and targeted BsAb-Cy5 labelled 
HBP conjugate (targeted) (n=3). 1 control mice (untreated) was prepared as a control mouse. The 
BsAb and Cy5 labelled HBP was mixed (1:1 molar ratio) in phosphate buffer saline and incubated at 
room temperature 1 h prior injection. The final concentration of Cy5 labelled HBP in injection 
formulation was 3 mg/mL. The mice were anaesthetized and injected via the tail vein with 200 µl 
injection volume. The fluorescence imaging was performed at 4, 24, 48 h and 5 days post-injection. 
Mice were anaesthetized during all procedures and imaged on an IVIS Lumina X5 imaging system 
(PerkinElmer Inc., Waltham, MA, USA) and analyzed using the Living Image software (PerkinElmer 
Inc.) at excitation 620 nm and emission filter of 670 nm. After 5 days, all the mice were euthanized 
and ex vivo images were performed using the same imaging protocols. All the fluorescence intensity 
data of the tumors and organs of treated mice were normalized into data of control (untreated) mouse. 
 
5.2.4 In vivo biodistribution and selective tumor uptake of antibody fragment-dye conjugate 
using J591 scFv pAzF-Cy7 labelled DBCO in tumor bearing mice in comparison with BsAb-
Cy5 labelled HBP  
 
 All the xenograft mice models were prepared as protocol above. BsAb-Cy5 labelled HBP as 
formula above, and J591 scFv pAzF at the concentration 10 µM were conjugated into Cy7 labelled 
DBCO via copper free click chemistry reaction in 1:1 molar ratio at 4 °C overnight. Following this, 
6 xenograft mice with PC3 and PC3-PIP tumors were anaesthetized using 2% isofluorane and were 
co-injected with BsAb-Cy5 labelled HBP and J591 scFv pAzF-Cy7 labelled DBCO formula via the tail 
vein with 200 µl of total injection volume. 1 control mice (untreated) was prepared as a control mouse. 
The co-injected mice were split into 3 groups based on observation time, including 1-hour post 
injection (hpi), 4 hpi, and 24 hpi, with two mice for each group. Mice were anaesthetized during all 
time points and imaged on an IVIS Lumina X5 imaging system (PerkinElmer Inc., Waltham, MA, 
USA), followed by data analysis using the Living Image software (PerkinElmer Inc.). The 
620Ex/670Em and 720 Ex/790Em were used to analyze Cy5 fluorescence at Bsab-Cy5 labelled HBP 
and Cy7 fluorescence at J591 scFv-pAzF-Cy7 labelled DBCO respectively.  Following the 
fluorescence live imaging, the mice were euthanized for ex vivo imaging in each group.  The ex vivo 
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images were performed using the same imaging protocols. All the fluorescence intensity data of the 
tumors and organs of treated mice were normalized into data of control (untreated) mouse. 
 
5.3 Results 
 
5.3.1 In vivo biodistribution and tumor uptake of BsAb-HBP conjugate in tumor bearing mice 
models 
 
To investigate in vivo biodistribution and tumor uptake of BsAb-HBP conjugate, the images of mice 
were captured at 4, 24, 48 h and 5 days after administration with 200 µl of BsAb-HBP conjugate (1:1 
in molar ratio), and HBP alone as a control at concentration 3mg/mL. As shown in Figure 5.1 A, the 
fluorescent intensity was primarily found in PC3-PIP (PSMA positive) cells; however, both BsAb-
HBP conjugate and HBP alone gave the similar behavior in tumor uptake. It is presumably because 
of EPR effect.  It was also observed from the 6 mice that the highest tumor targeting occurred in the 
BsAb-HBP targeted mouse 3. The high level of targeting in this mouse was also maintained over 
time.  It was also observed that there was a slight improvement over time in tumor targeting in the 
BsAb-HBP cohort.  The difference between BsAb conjugated to HBP and unconjugated HBP was in 
the blood circulation, whereas the HBP alone has more intense fluorescence, meaning it has longer 
circulation in the body. In addition, ex vivo images after 5 days administration, shown in Figure 5.1 
B showed that fluorescence intensity of conjugated HBP was found higher in the clearance organs, 
such as kidney, liver and spleen compare to that for unconjugated HBP. For ex vivo tumors uptake, 
BsAb conjugated HBP has no significantly higher accumulation in PC3-PIP tumor compared to HBP 
alone. In contrast, the mean value is slightly higher for HBP comparing with BsAb conjugated HBP, 
seemingly due to EPR effect. However, based on the ROI ratio of PSMA positive to PSMA negative 
tumors, the BsAb conjugated HBP has the higher ratio with 2.4 compared to 1.6 for HBP alone (Table 
5.1). Region of interest (ROI) ratio is measuring the fluorescence intensity in positive xenograft tumor 
compared to negative xenograft tumor. The higher ROI ratio value indicated more accumulation in 
positive xenograft tumor. Therefore, it is suggested that the attachment of BsAb facilitated enhanced 
BsAb-HBP accumulation in PSMA positive tumor.   
 
 
 
 
 
 
62 
A 
B 
Figure 5.1: In vivo biodistribution and tumor accumulation of free Cy5 labelled HBP and J591-mPEG BsAb 
conjugated to Cy5 labelled HBP in xenograft tumor models of PSMA positive prostate cancer, PC3-PIP (left flank) 
and PSMA negative prostate cancer, PC3 (right flank). A) Mice were imaged at 4, 24, 48 h, and 5 days post injection 
with an in vivo imaging system (IVIS) spectrum after being intravenously administered with  J591-mPEG BsAb 
conjugated to Cy5 labelled HBP (1:1 in molar ratio) and Free Cy5 labelled HBP as a control. B) Ex vivo fluorescence of 
excised organs and tumors at 5 days post injections. Data represent mean (n=3) with standard deviation. The signal 
intensity of the tumors organs was measured by IVIS software and have been subtracted with the signal intensity of 
control mouse (untreated). 
Table 5.1 Region of interest (ROI) ratio of PSMA positive tumor (PC3-PIP) to PSMA negative tumor (PC3) at 5 
days after intravenous (i.v) injection of Cy5 labelled HBP alone and Cy5 labelled HBP conjugated to BsAb J591-
mPEG. 
i.v injection ROI ratio of PC3-PIP (PSMA +) to PC3 (PSMA -) tumors 
Cy5 labelled HBP 1.6 
BsAb-Cy5 labelled HBP conjugate 2.4 
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5.3.2 Comparison of J591 scFv-pAzF conjugated Cy7 labelled DBCO and J591-mPEG BsAb 
conjugated Cy5 labelled PEG HBP for imaging purposes 
 
 In this study, we also compared the PEGylated antibody fragment format BsAb-HBP 
conjugate with the non-PEGylated format scFv-pAzF-DBCO conjugate for in vivo imaging properties 
and their distribution to organs and tumor uptake in xenograft models. Different cyanine dyes 
labelling was utilized to distinguish these two different formats, including a far-red fluorescent Cy5 
attached on polymer for BsAb-PEG HBP and a near infra-red Cy7 attached on DBCO for scFv-pAzF-
DBCO. The two formulas were co-injected into the same mouse, and the biodistribution profile and 
tumor uptake were evaluated at 1 h, 4 h, and 24 h post injection under Cy5 and Cy7 channel at the 
same time. The Cy5 channel corresponds to BsAb-HBP, while Cy7 channel corresponds to scFv-
pAzF-DBCO. In general, in vivo data showed that both BsAb-HBP and scFv-pAzF DBCO 
specifically targeted PSMA positive xenograft. However, as shown in previous data, the accumulation 
of BsAb- HBP were also detected in PSMA negative tumors especially at 24 hpi. The scFv pAzF-
DBCO showed high clearance through the kidney as early as 1 hpi. By 24 h, the signal in kidney was 
more intense, and the fluorescence started clearing in blood circulation as well as in xenograft tumor. 
In contrast, the kidney clearance was barely seen in BsAb-HBP conjugate, even after 24 h, and the 
fluorescence was still in the blood circulation with an increased accumulation into PSMA positive 
xenograft (Figure 5.2)   
 Data were supported by ex vivo images results. The scFv-pAzF-DBCO targeted PSMA 
positive xenograft with the higher fluorescence intensity were detected at 4 hpi and the signal started 
clearing after 24 hpi. For the negative PSMA xenograft, the signal was lower than in positive 
xenograft and relatively in the same intensity. The fluorescence was mostly detected in kidneys, and 
continually increased until 24 hpi. In contrast, the fluorescence continually decreased in blood, and 
other organs including heart, lung, liver and spleen after 24 hpi. Interestingly, the fluorescence 
intensity in liver was also relatively higher compared to other organs, and tumors (Figure 5.3 A). The 
BsAb-HBP format also targeted PSMA positive xenograft, with higher fluorescence intensity 
compared to negative xenograft and increased after 4 and 24 hpi. In agreement with in vivo results, 
after 24 h, the fluorescence intensity of the BsAb also started rising in PSMA negative xenograft. For 
the organ’s accumulation, the higher fluorescence were detected in blood, followed by lungs and 
kidneys (Figure 5.3 B).     
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Figure 5.2: Comparison of in vivo profile of J591 scFv-pAzF and J591-mPEG BsAb-HBP conjugate in xenograft 
tumor mice models bearing PSMA positive PC3-PIP (left flank) and PSMA negative PC3 (right flank). Mice were 
co-injected with J591 scFv-pAzF-Cy7 labelled DBCO conjugate and J591-mPEG BsAb-Cy5 labelled HBP conjugate. 
Images were taken at 1, 4, and 24 hours post-injection of. Images under Cy7 channel (720Ex/790Em) (top) and Cy5 
channel (620Ex/670Em) (bottom) represent in vivo biodistribution of J591 scFv-pAzF and J591-mPEG BsAb-HBP 
conjugate respectively.  
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Figure 5.3: Ex vivo fluorescence of excised organs and tumors at 1, 4, and 24 hours post injection. A) Fluorescence 
quantification of the organs and tumors through Cy7 channel (ex=720 nm; em= 790 nm), detecting J591-pAzF-DBCO 
conjugate (n=2, with standard deviation). B) Fluorescence quantification of the organs and tumors through Cy5 channel 
(ex= 620 nm; em= 670 nm), detecting J591-mPEG BsAb-HBP conjugate (n=2, with standard deviation). The signal 
intensity of the tumors organs was measured by IVIS software and have been subtracted with the signal intensity of 
control mouse (untreated). 
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5.4 Discussion 
 
 We evaluated the in vivo biodistribution and tumor accumulation of bioconjugates in 
xenograft mice models, including PEGylated format in BsAb-HBP and non-PEGylated format in 
scFv-DBCO. For the BsAb-HBP format, in vivo tumor uptake study demonstrates that after 5 days 
post injection, J591-mPEG BsAb-HBP conjugate was primarily accumulated and retained in PSMA 
positive xenograft tumor. In comparison with HBP alone, biodistribution of BsAb-HBP bioconjugate 
demonstrates an increased localization in clearance organs, such as liver, kidney and spleen. One of 
the undesirable effects of attaching active targeting ligand into nanomaterials is non-specific binding 
and increased uptake within reticuloendothelial system (RES) organs, such as spleen, lungs and liver, 
as well as kidneys [233]. In agreement with that, the attachment of BsAb into HBP as active targeting 
nanocarrier may display non-specific binding and increase uptake into clearance organs, resulting in 
shorter circulation time. Consequently, the cellular internalization and uptake into tumor cells will be 
not optimal. On the other hand, the longer blood circulation of unconjugated HBP increase the 
opportunity for tumor extravasation [234], resulting the enhanced accumulation through the utilization 
of EPR effect. Although, the BsAb conjugated HBP does not lead to a significant improvement in 
tumor accumulation in vivo, compared to HBP alone, after 5 days post injections, the fluorescent 
intensity (ROI ratio) of BsAb-HBP conjugate in PSMA positive xenograft tumor (PC3-PIP) was 2.4-
fold greater than in PSMA negative xenograft tumor (PC3), compared to 1.6-fold greater for HBP 
alone (Table 5.1). These data may indicate the targeting selectivity of BsAb-HBP conjugate, thereby 
facilitating enhanced tumor internalization and accumulation via receptor-mediated endocytosis 
pathway [62]. Based on in vitro cellular uptake by flow cytometry (Figure 2.5), the increased BsAb 
amount conjugated into HBP results in increased cell targeting, with optimum molar ratio of 
BsAb:HBP was about 5:1. In this in vivo study, 1:1 of molar ratio was used since the highly 
concentrated of BsAb forms protein aggregates. Therefore, we could not prepare the injection 
formulation with high molar ratio of BsAb:HBP (5:1). The optimum density of BsAb in BsAb-HBP 
conjugate is anticipated to increase the avidity of antibody into receptor target in tumor which can aid 
rapid internalization and enhanced tumor accumulation. However, Cui et.al. reported that BsAb 
functionalization PEG particles results in different behavior in vitro and in vivo. The large amount of 
BsAb influenced the stealth properties of BsAb-PEG conjugate, resulting in off-target accumulation, 
whereas the increased accumulation of BsAb-PEG conjugate was found in spleen, liver and lungs 
rather than in positive tumor xenograft [194].    
 Co-injection of BsAb-HBP and scFv-pAzF DBCO into the same mouse were performed to 
evaluate the difference in in vivo biodistribution, and tumor accumulation of these two formats in 
xenograft mice models.  This is also the first time that an antibody conjugated to Cy7 dye site 
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specifically via azide bearing unnatural amino acid has been trialed in vivo.  In general, both designs 
have target specificity into PSMA expressing xenograft. The differences were observed in blood 
circulation time and organs biodistribution, especially in clearance organs. The rapid clearance and 
shorter circulation time was expected in non-PEGylated scFv format, as frequently reported in many 
studies due to the small MW [188, 226, 235].  However, the rapid renal clearance of this format is ideal 
for tumor diagnostic imaging and radiotherapy applications. The high ratio of tumor-to-background 
attained at early time points is more desired as imaging tracers [236]. The extremely high fluorescence 
intensity in the kidneys was observed presumably due to the excess of unconjugated small molecule 
DBCO-Cy7 in the solution which has a fast clearance through the kidneys. The higher accumulation 
of scFv-pAzF DBCO was also found in the liver at early time point, even though, the scFv generally 
do not accumulate in the liver [237-239]. The excess unconjugated imaging dye might be the reason for 
higher intensity as the fluorescence dye uptake might be retained longer in the liver.  
 In contrast, the BsAb-HBP conjugate which is a PEGylated format has stealth properties 
avoiding rapid renal  clearance and has  a prolong circulation time [240]. Moreover, the multiple 
attachment sites of the BsAb-HBP formula may increase the avidity to target receptors, resulting in 
longer interaction on tumor sites and improved tumor accumulation. When this formula is used as 
targeted nanocarrier for drug delivery, a longer blood circulation may facilitate a longer time for the 
drugs to interact on the tumor sites. Therefore, this formula could be more valuable as theranostics 
applications, combining tumor diagnostic imaging and targeted drug delivery for therapy.  
 
5.5 Conclusion 
 
 In this study, we examined in vivo imaging profiles, including the xenograft accumulation, 
biodistribution and clearance properties of two antibody conjugate formats, including J591-mPEG 
BsAb conjugated Cy5 labelled HBP, and J591 scFv-pAzF conjugated to Cy7 labelled DBCO. In 
general, we confirmed that both formats have shown the successful targeting into PSMA positive 
xenograft mice models. However, we observed the differences between PEGylated and non-
PEGylated, and between single and multiple attachment site of antibody fragment for tumor 
accumulation, and biodistribution in other organs, including clearance organ (kidney), as well as RES 
organs (liver, spleen). Single attachment of scFv without PEGylation in J591-scFv-pAzF conjugated 
to Cy7 labelled DBCO showed a shorter circulation time which is expected due to the small size of 
this scFv-imaging dye conjugate (~28 kDa). Such design, however, is ideal to apply as imaging 
tracers. On the other hand, PEGylated format with multiple attachment sites of antibody fragment in 
BsAb-Cy5 labelled HBP conjugate demonstrated a longer half-life which provide enough time to 
accumulate in target tumor site. This benefit is essential for therapeutic application. However, this 
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study suggested that enhanced tumor accumulation is influenced by combination of longer half-lives 
and EPR effect, since it is also achieved by non-targeted agent, unconjugated HBP. In addition, BsAb 
functionalization PEGylated HBP increase in liver and spleen accumulation, resulting in reduction of 
tumor accumulation.  
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Chapter 6 Concluding remarks  
 
NPs have potential as the next generation of nanomedicine, offering a number of applications 
to overcome the challenges in diagnosis, monitoring, prevention, and treatment of various diseases, 
particularly in cancer medicine. The potential to apply actively targeted therapeutics through 
conjugation of NPs with antibody targeting specific disease antigens opens up research possibilities 
exploring novel and simple conjugation methods, where a stable antibody-NP conjugate is crucial for 
successful targeting. During this project, we have successfully engineered two novel bioconjugation 
strategies, involving non-covalent and covalent conjugation methods to obtain a stable conjugate. 
Both these methods provide a simpler way to attach antibody fragments to NPs compared to current 
chemical and enzymatic based conjugation strategies which require rigorous optimization, validation 
and the generation of multiple reagents.  In addition, this is the first time that unnatural amino acids 
incorporated into an antibody fragment have been applied in an in vivo imaging experiment and also 
the first time where two novel methods have been compared head to head in an in vivo cancer model. 
In this study we developed two bioconjugation formats.  The first is a BsAb format, consisting 
of two scFvs, one scFv targets PSMA receptor and the other scFv targets methoxy-PEG (mPEG) 
nanomaterials. The BsAb, produced in mammalian cells, demonstrated binding specificity to PSMA 
expressing prostate cancer cells and non-covalent conjugation to m-PEG based HBP through simple 
mixing of BsAb with HBP which resulted in homogenous bioconjugates and overcomes potential 
instability of antibody-NP conjugate resulting from chemical conjugation. Furthermore, the HBP 
used in this study has versatile design which can be functionalized with various cargos, such as 
imaging agents and therapeutic drugs.  Several in vitro analyses exhibited that the bioconjugate 
specifically targets and internalizes into PSMA positive prostate cancer cells and showed enhanced 
cellular uptake, demonstrated by confocal microscopy using PSMA positive prostate cancer cells. 
Moreover, in vitro cytotoxicity study showed that the BsAb-conjugated to Dox loaded HBP can 
enhance drug accumulation and cytotoxic effect compared to that unconjugated HBP, meaning this 
BsAb-HBP conjugate has major benefits as an actively targeted drug delivery system. The BsAb-
HBP conjugate demonstrated a slight improvement in tumor targeting in xenograft mice models 
compared to HBP alone, while also increased liver and spleen accumulation. This result shows that 
functionalization of BsAb into PEGylated HBP can exhibit different biological behaviors between in 
vitro and in vivo. Therefore, further investigation of the BsAb structure and stability, and optimization 
of BsAb or mPEG HBP density in the bioconjugate will identify the optimal formulation of this 
hybrid material for targeted diagnosis and therapy. 
The second bioconjugation format focuses on a covalent conjugation that has been achieved 
via copper click chemistry reaction between azide-modified anti-PSMA J591 scFv and DBCO 
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functionalized NPs/imaging dye. In vitro incorporation of UAA to obtain azide-modified J591 scFv, 
provide selective labelling in the intracellular environment, resulting in a stable functionalized 
protein. We confirmed that a copper-free click chemistry reaction for antibody-NPs/imaging dye 
conjugate results in a stable conjugate under mild condition. Furthermore, in vitro studies confirmed 
the specific targeting of this antibody fragment-imaging dye conjugate into PSMA expressing 
prostate cancer cells. In vivo and ex vivo studies of azide-modified J591 scFv-imaging dye DBCO 
conjugate demonstrated high binding affinity into xenograft tumor target with rapid renal clearance, 
which may be more ideal for application as imaging tracers. We also demonstrated the ability to attach 
azide-modified J591 scFv to larger structures such as a DBCO containing thermo-responsive PEG 
based polymer in micellar system.  This is very important for improvement of antibody half-life (via 
PEGylation) and binding affinity. Longer half-life would enhance time for target binding, and likely 
provide a more homogenous distribution into tumor sites. One major design consideration for targeted 
NPs is avoiding immune recognition. NPs injection via intravenous are often taken up by monocytes 
in the bloodstream or in the tumor microenvironment, and subsequently eliminated through the RES 
system, including lung, liver and spleen.  By using click chemistry in combination with larger PEG 
polymer systems, there is potential to customize NPs with targeting ligands via site specific 
conjugation of scFv-azide to DBCO groups.  This enables a systematic approach to balance and 
control targeting ligand density, placement and coverage on a PEG NP to maintain PEG stealth 
properties and avoid clearance and potentiate tumor targeting. This concept using DBCO- PEG 
polymer in combination with the UAA scFvs developed in this project is the basis of a paper that is 
currently under review by ACS Nano, “Controlling the biological fate of micellar nanoparticles: 
Balancing stealth and targeting” 
 The potential benefit of copper-click chemistry reaction has led to the utilization of azide-
modified scFv via UAA incorporation for other bioconjugation methods. Our group are currently 
developing the bioconjugation of azide-modified scFvs into DBCO containing toxin for targeting 
glioma for antibody drug conjugate application.  For further investigation, we are determining the 
efficiency of conjugation for optimal bioconjugate design. 
In summary, this study has contributed to the bio-nanomaterial research field by developing 
novel bioconjugation strategies for the simple generation of antibody-nanomaterial conjugates for 
application as actively targeted drug delivery tools, as well as complex imaging contrast agent for 
diagnosis purposes. These advances will contribute in the generation of an era targeted cancer 
diagnosis and therapy as a precision nanomedicine.  
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APPENDICES 
 
Appendix A: Supplementary data for Chapter 3 
 
MGWSCIILFLVATATGVHSHHHHHHEVQLQQSGPELVKPGTSVRISCKTSGYTFTEYTIHW
VKQSHGKSLEWIGNINPNNGGTTYNQKFEDKATLTVDKSSSTAYMELRSLTSEDSAVYYC
AAGWNFDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVMTQSHKFMSTSVGDRVSIICKA
SQDVGTAVDWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLAITNVQSEDLAD
YFCQQYNSYPLTFGAGTKLEIKRGGGGSEVKLEESGGGLVQPGGSMKLSCVAEESGGGLV
QPGGSMKLSCVASGFTFSNYWMNWVRQSPEKGLEWVTEIRSKSNNYATHYAESVKGRFTI
SRDDSKGSVYLQMNNLRAEDTGIYYCSNRYYWGQGTLVTVSAGGGGSGGGGSGGGGSDI
VMTQSHKFMSTSVRDRVTITCKASQDVNTSVAWYQQKPGQSPKLVIYWASTRHTGVPDR
FTGSGSGTDFTLTISNVQSEDLADYFCLQYINYPYTFGGGTKLEIKEQKLISEEDLN* 
 
Figure A.1: The BsAb J591-mPEG design. Signal Peptide -His6x- J59 Vh -(G4S)3- J591 Vk -G4S- anti-methoxyl-PEG 
Vh -(G4S)3- anti-methoxyl-PEG Vk -cMyc-Tag* 
 
 
 
 
 
 
 
 
 
 
 
Figure A.2: SEC profile of protein standard (BioRad) with elution buffer 1xPBS in 20% ethanol. 
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Figure A.3: Protein Identification and analysis tools using the ExPASy server. 
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Figure A.4: The prediction of disorder protein sequence using algorithm by PONDR® protein disorder predictor 
[241, 242]. About 22.5 % of the BsAb protein sequences are predicted to be intrinsically disordered regions (IDRs). 
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